Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type	Study_count
Total_Studies	2620
interventional	2294
Observational	300
Registry	26

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type	Study_Count
Drug	1309
Drug\|placebo	143
Drug\|Radiation	121
Biological\|Drug	107
Biological	81
Radiation	76
Drug\|Other	59
Procedure	49
Drug\|Procedure	43
Other	35
Biological\|Drug\|Other	21
Drug\|Procedure\|Radiation	19
Device	18
Behavioral	13
Biological\|Drug\|placebo	13
Biological\|Drug\|Radiation	11
Biological\|Other	11
Diagnostic Test	9
Drug\|Other\|placebo	9
Drug\|Other\|Procedure	9
Drug\|placebo\|Radiation	8
Other\|Procedure	8
Procedure\|Radiation	8
Biological\|placebo	7
Device\|Drug	7
Drug\|Other\|Radiation	7
Biological\|Radiation	6
Other\|Radiation	6
Combination Product	5
Other\|Procedure\|Radiation	5
Dietary Supplement	4
Behavioral\|Other\|Procedure	3
Biological\|Other\|Radiation	3
Diagnostic Test\|Drug	3
Drug\|Genetic\|Other	3
Drug\|Other\|Procedure\|Radiation	3
Genetic	3
Behavioral\|Drug\|placebo	2
Biological\|Dietary Supplement\|Drug	2
Biological\|Drug\|Other\|placebo	2
Biological\|Drug\|Other\|Radiation	2
Biological\|Other\|Procedure\|Radiation	2
Combination Product\|Drug	2
Device\|Drug\|Radiation	2
Device\|Other	2
Dietary Supplement\|Drug	2
Drug\|Genetic\|Other\|Procedure	2
Behavioral\|Drug\|Other\|placebo	1
Behavioral\|Drug\|Other\|Procedure	1
Behavioral\|Radiation	1
Biological\|Combination Product\|Drug\|Other	1
Biological\|Device	1
Biological\|Device\|Drug\|Radiation	1
Biological\|Diagnostic Test	1
Biological\|Drug\|Genetic\|Other	1
Biological\|Drug\|Other\|Procedure	1
Biological\|Drug\|placebo\|Radiation	1
Biological\|Drug\|Procedure	1
Biological\|placebo\|Radiation	1
Biological\|Procedure	1
Combination Product\|Other	1
Device\|Drug\|Other	1
Device\|Drug\|Other\|Procedure	1
Device\|Drug\|Procedure\|Radiation	1
Device\|Other\|Radiation	1
Device\|Procedure	1
Device\|Radiation	1
Diagnostic Test\|Drug\|Other	1
Diagnostic Test\|Other\|Procedure	1
Dietary Supplement\|Drug\|Radiation	1
Dietary Supplement\|placebo	1
Drug\|Genetic	1
Drug\|Genetic\|Other\|placebo	1
Drug\|Genetic\|Other\|Procedure\|Radiation	1
Drug\|Genetic\|Procedure	1
Drug\|Other\|placebo\|Procedure	1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country	Study_Count
United States	861
China	270
NA	83
France	75
Canada	49
Japan	41
United States\|Canada	40
Korea, Republic of	38
Italy	30
United Kingdom	30
Germany	29
Netherlands	28
Taiwan	21
Greece	18
Spain	15
Belgium	14
Australia	13
Denmark	10
Switzerland	9
India	7
United States\|Spain	7
Israel	6
Poland	6
Singapore	6
United States\|Germany	6
United States\|United Kingdom	6
Norway	5
Russian Federation	5
United States\|Puerto Rico	5
United States\|China	4
Austria	3
Brazil	3
Sweden	3
United States\|France	3
United States\|India	3
United States\|Korea, Republic of	3
United States\|Netherlands	3
Argentina	2
China\|Japan\|Korea, Republic of\|Taiwan	2
China\|Korea, Republic of\|Taiwan	2
China\|Korea, Republic of\|Thailand	2
Finland	2
France\|Germany	2
Germany\|Switzerland	2
Hong Kong	2
Hong Kong\|Korea, Republic of\|Singapore\|Taiwan\|Thailand	2
Mexico	2
Romania	2
Turkey	2
United States\|Australia	2
United States\|Australia\|Brazil\|Bulgaria\|Canada\|China\|France\|Germany\|Greece\|Hong Kong\|Hungary\|Ireland\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Poland\|Russian Federation\|Spain\|Sweden\|Taiwan\|United Kingdom	2
United States\|Australia\|Canada	2
United States\|Australia\|Japan\|Korea, Republic of	2
United States\|Australia\|Korea, Republic of\|Taiwan	2
United States\|Australia\|Peru\|Puerto Rico	2
United States\|Canada\|France\|Germany\|Italy\|Spain\|United Kingdom	2
United States\|Canada\|Puerto Rico	2
United States\|Canada\|Spain\|United Kingdom	2
United States\|France\|Hungary\|Poland\|Spain	2
United States\|Georgia\|India\|Russian Federation\|Ukraine	2
United States\|Italy	2
United States\|Japan	2
United States\|Russian Federation	2
United States\|Taiwan	2
NA	1
Argentina\|Australia\|Austria\|Belgium\|Brazil\|China\|Finland\|France\|Germany\|Hungary\|India\|Israel\|Italy\|Korea, Republic of\|Mexico\|Netherlands\|Peru\|Poland\|Russian Federation\|Spain\|Taiwan\|Ukraine\|United Kingdom	1
Argentina\|Australia\|Austria\|Brazil\|China\|Colombia\|Denmark\|France\|Germany\|Greece\|Hungary\|India\|Ireland\|Italy\|Japan\|Korea, Republic of\|Lebanon\|Mexico\|Netherlands\|Norway\|Poland\|Portugal\|Russian Federation\|Singapore\|Spain\|Sweden\|Taiwan\|Thailand\|Turkey\|United Kingdom	1
Argentina\|Australia\|Belgium\|Brazil\|Bulgaria\|Canada\|Czech Republic\|France\|Germany\|Greece\|Hong Kong\|Hungary\|Israel\|Italy\|Poland\|Russian Federation\|Spain\|Taiwan\|Thailand\|United Kingdom	1
Argentina\|Australia\|Brazil\|Canada\|Romania\|Singapore	1
Argentina\|Belgium\|Brazil\|Bulgaria\|Canada\|China\|Colombia\|Czechia\|Denmark\|Germany\|India\|Ireland\|Italy\|Kazakhstan\|Luxembourg\|Mexico\|Poland\|Portugal\|Romania\|Slovakia\|Spain\|Switzerland\|United Kingdom\|Vietnam	1
Argentina\|Brazil\|Chile\|Mexico	1
Argentina\|Brazil\|China\|Colombia\|Costa Rica\|Denmark\|Greece\|Guatemala\|Italy\|Latvia\|Lebanon\|Malaysia\|Mexico\|Morocco\|Netherlands\|Panama\|Peru\|Philippines\|Poland\|Slovenia\|Spain\|Sweden\|United Arab Emirates\|United Kingdom	1
Australia\|Austria\|Belgium\|Canada\|Chile\|China\|Czech Republic\|Denmark\|France\|Germany\|Greece\|Hungary\|Italy\|Korea, Republic of\|Lithuania\|Malaysia\|New Zealand\|Poland\|Romania\|Russian Federation\|Slovakia\|Slovenia\|South Africa\|Spain\|Ukraine\|United Kingdom\|Venezuela	1
Australia\|Austria\|Czechia\|Greece\|Hungary\|Israel\|Italy\|Poland\|Portugal\|Russian Federation\|Spain	1
Australia\|Belgium\|Canada\|Czech Republic\|Denmark\|France\|Germany\|Hong Kong\|Hungary\|Italy\|Netherlands\|Poland\|Russian Federation\|Spain\|Taiwan\|United Kingdom	1
Australia\|Belgium\|China\|France\|Germany\|Israel\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Singapore\|Spain\|Taiwan\|Thailand	1
Australia\|Belgium\|China\|Germany\|Japan\|Singapore\|Spain	1
Australia\|Belgium\|Finland\|France\|Germany\|Greece\|India\|Italy\|Netherlands\|Poland\|Portugal\|Romania\|Spain\|Turkey\|United Kingdom	1
Australia\|Belgium\|France\|India\|Japan\|Malaysia\|Spain\|Taiwan\|Thailand	1
Australia\|Belgium\|France\|Italy\|Korea, Republic of\|Lithuania\|Netherlands\|Poland\|Romania\|Singapore\|Spain\|Taiwan\|United Kingdom	1
Australia\|Belgium\|Germany	1
Australia\|Brazil\|China\|Korea, Republic of\|Mexico\|Taiwan	1
Australia\|Brazil\|Czech Republic\|France\|Germany\|Italy\|Korea, Republic of\|South Africa\|Taiwan\|United Kingdom	1
Australia\|Canada	1
Australia\|Canada\|Czech Republic\|Netherlands\|United Kingdom	1
Australia\|China\|Egypt\|India\|Korea, Republic of\|Romania\|Taiwan\|Turkey	1
Australia\|China\|Hong Kong\|Indonesia\|Korea, Republic of\|Philippines\|Taiwan\|Thailand	1
Australia\|China\|Korea, Republic of	1
Australia\|Hong Kong\|Korea, Republic of\|Singapore	1
Australia\|Italy\|Mexico\|Spain	1
Australia\|Korea, Republic of\|Malaysia	1
Australia\|Netherlands\|Singapore	1
Australia\|New Zealand	1
Australia\|New Zealand\|Poland\|Russian Federation\|Thailand	1
Australia\|New Zealand\|Spain	1
Australia\|Singapore	1
Australia\|Taiwan	1
Australia\|United Kingdom	1
Australia\|United States\|Austria\|Belarus\|Brazil\|Canada\|Croatia\|Czechia\|Denmark\|Egypt\|Estonia\|Finland\|France\|Germany\|Greece\|Hungary\|Ireland\|Israel\|Italy\|Latvia\|Lithuania\|Mexico\|Netherlands\|New Zealand\|Norway\|Poland\|Portugal\|Puerto Rico\|Russian Federation\|Serbia\|Slovakia\|South Africa\|Spain\|Sweden\|Switzerland\|Turkey\|Ukraine\|United Kingdom	1
Austria\|Australia\|Belgium\|Canada\|China\|Czech Republic\|Denmark\|Finland\|France\|Germany\|Greece\|Hungary\|Israel\|Italy\|Latvia\|Lithuania\|Netherlands\|New Zealand\|Philippines\|Poland\|Portugal\|Russian Federation\|Singapore\|South Africa\|Spain\|Switzerland\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
Austria\|Belgium\|Denmark\|France\|Germany\|Netherlands\|Norway\|Switzerland\|United Kingdom	1
Austria\|Belgium\|Denmark\|Greece\|Hungary\|Ireland\|Israel\|Italy\|Netherlands\|Spain\|Switzerland\|United Kingdom	1
Austria\|Belgium\|France\|Germany\|Ireland\|Italy\|Poland\|Slovenia\|Spain\|Switzerland\|United Kingdom	1
Austria\|Denmark\|Finland\|Greece\|Hungary\|Ireland\|Poland\|Portugal\|Romania\|Russian Federation\|Spain\|Sweden\|United Kingdom	1
Austria\|Denmark\|France\|Germany\|Italy\|Spain	1
Austria\|Germany\|Greece\|Italy\|Netherlands\|Spain	1
Austria\|Germany\|Hungary\|Spain\|Sweden	1
Bahamas\|Canada	1
Bangladesh	1
Belarus\|Bulgaria\|Croatia\|Georgia\|Greece\|Hungary\|India\|Latvia\|Malaysia\|Philippines\|Poland\|Russian Federation\|Serbia\|Slovakia\|Thailand\|Turkey\|Ukraine	1
Belarus\|Georgia\|Germany\|Hungary\|Korea, Republic of\|Poland\|Romania\|Russian Federation\|Serbia\|Spain\|Taiwan\|Thailand\|Ukraine	1
Belarus\|Hungary\|Poland\|Russian Federation\|Ukraine	1
Belarus\|India\|Russian Federation\|Ukraine	1
Belarus\|Russian Federation	1
Belgium\|Bosnia and Herzegovina\|Bulgaria\|Egypt\|Estonia\|Germany\|Hungary\|Italy\|Lithuania\|Poland\|Romania\|Saudi Arabia\|Slovakia\|Sweden\|Taiwan	1
Belgium\|Bulgaria\|Estonia\|France\|Germany\|Hong Kong\|Ireland\|Italy\|Poland\|Russian Federation\|Singapore\|Spain\|Taiwan\|United Kingdom	1
Belgium\|Bulgaria\|France\|Germany\|Hong Kong\|Hungary\|Italy\|Korea, Republic of\|Norway\|Poland\|Portugal\|Russian Federation\|Slovakia\|Spain\|Turkey	1
Belgium\|China\|France\|Germany\|Greece\|Hungary\|Italy\|Korea, Republic of\|Netherlands\|Poland\|Portugal\|Spain\|Taiwan\|Thailand\|United Kingdom	1
Belgium\|Czech Republic\|Egypt\|France\|Germany\|Greece\|Italy\|Netherlands\|Poland\|South Africa\|Spain\|Switzerland	1
Belgium\|Czech Republic\|France\|Germany\|Ireland\|Italy\|Poland\|Spain	1
Belgium\|Denmark\|Netherlands\|Sweden\|United Kingdom	1
Belgium\|Estonia\|Finland\|France\|Germany\|Greece\|Italy\|Latvia\|Lithuania\|Netherlands\|Norway\|Poland\|Spain\|United Kingdom\|	1
Belgium\|France	1
Belgium\|France\|Germany\|Italy\|Poland\|Spain\|United Kingdom	1
Belgium\|France\|Greece\|Spain	1
Belgium\|France\|Italy\|Netherlands\|United Kingdom	1
Belgium\|France\|Spain	1
Belgium\|Germany\|Luxembourg	1
Belgium\|Germany\|Netherlands	1
Belgium\|Germany\|Netherlands\|Spain\|Switzerland	1
Belgium\|Germany\|Switzerland\|United Kingdom	1
Belgium\|Ireland\|Italy\|Netherlands\|Spain\|Switzerland	1
Belgium\|Ireland\|Spain	1
Belgium\|Netherlands	1
Belgium\|Netherlands\|United Kingdom	1
Belgium\|Spain	1
Belgium\|Spain\|United Kingdom	1
Belgium\|United States\|Argentina\|Australia\|Brazil\|Canada\|Chile\|China\|Czechia\|Denmark\|France\|Germany\|Greece\|Hungary\|Israel\|Italy\|Japan\|Jordan\|Korea, Republic of\|Lebanon\|Netherlands\|Poland\|Russian Federation\|Singapore\|Spain\|Taiwan	1
Belgium\|United States\|Argentina\|Chile\|France\|Germany\|Hungary\|India\|Italy\|Netherlands\|Norway\|Poland\|Puerto Rico\|Romania\|Russian Federation\|South Africa\|Spain\|Sweden\|Switzerland\|Taiwan\|United Kingdom	1
Brazil\|Bulgaria\|Chile\|Georgia\|Greece\|Hungary\|India\|Lebanon\|Malaysia\|Mexico\|Philippines\|Russian Federation\|Serbia\|Spain\|Thailand\|Turkey\|Ukraine	1
Brazil\|Bulgaria\|China\|Lithuania\|Mexico\|New Zealand\|Poland\|Russian Federation\|Slovakia\|Turkey	1
Brazil\|Canada	1
Brazil\|China\|Hong Kong\|India\|Korea, Republic of\|Taiwan\|United Kingdom	1
Bulgaria	1
Bulgaria\|Czech Republic\|France\|Romania\|Ukraine	1
Bulgaria\|France\|Greece\|Hungary\|Italy\|Norway\|Poland\|Portugal\|Romania\|Spain\|Switzerland\|Turkey\|United Kingdom	1
Canada\|Germany\|Hong Kong\|Italy\|Singapore\|Taiwan	1
Canada\|Hungary\|Poland\|Romania	1
Canada\|Italy	1
Canada\|Korea, Republic of\|Taiwan	1
Canada\|United States\|Brazil\|Germany\|Korea, Republic of\|Poland\|Romania\|Russian Federation\|United Kingdom	1
Canada\|United States\|Japan\|Romania\|South Africa	1
Chile\|China\|Croatia\|Egypt\|India\|Malaysia\|Malta\|Morocco\|Pakistan\|Panama\|Peru\|South Africa\|Tunisia	1
Chile\|France\|Italy\|Korea, Republic of\|Latvia\|New Zealand\|Poland\|Spain\|United Kingdom	1
China\|Austria\|Belarus\|Belgium\|Bulgaria\|Croatia\|Czechia\|Denmark\|France\|Georgia\|Germany\|Greece\|India\|Israel\|Italy\|Korea, Republic of\|Lithuania\|Poland\|Portugal\|Romania\|Russian Federation\|Slovakia\|South Africa\|Spain\|Switzerland\|Ukraine\|United Kingdom	1
China\|Denmark\|Egypt\|France\|Germany\|Netherlands\|Spain\|Switzerland\|Turkey	1
China\|France\|Germany\|Hong Kong\|Hungary\|Italy\|Japan\|Korea, Republic of\|Russian Federation\|Spain\|Taiwan	1
China\|Hong Kong\|India\|Philippines\|Taiwan\|Thailand\|Vietnam	1
China\|Hong Kong\|India\|Singapore\|Taiwan	1
China\|Hong Kong\|Indonesia\|Japan\|Malaysia\|Philippines\|Singapore\|Taiwan\|Thailand	1
China\|Hong Kong\|Indonesia\|Korea, Republic of\|Philippines\|Taiwan\|Thailand	1
China\|Hong Kong\|Malaysia\|Taiwan\|Thailand	1
China\|Hong Kong\|Russian Federation\|Singapore	1
China\|Italy\|Korea, Republic of\|Malaysia\|Singapore\|Spain\|Taiwan	1
China\|Korea, Republic of	1
China\|Korea, Republic of\|Malaysia\|Singapore\|Thailand	1
China\|Malaysia	1
China\|Malaysia\|Philippines	1
China\|Thailand	1
China\|United States\|Australia\|Belgium\|Brazil\|Bulgaria\|Canada\|Czechia\|France\|Germany\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Malaysia\|Philippines\|Poland\|Portugal\|Romania\|Russian Federation\|Spain\|Sweden\|Switzerland\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom\|Vietnam	1
China\|United States\|Australia\|Belgium\|Brazil\|Canada\|France\|Germany\|Hong Kong\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Poland\|Romania\|Russian Federation\|Spain\|Sweden\|Taiwan\|Thailand\|Turkey\|Ukraine\|Vietnam	1
China\|United States\|Australia\|Canada\|France\|Germany\|Hong Kong\|Hungary\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Russian Federation\|Spain\|Sweden\|Taiwan\|United Kingdom	1
Cyprus	1
Czech Republic\|Germany\|Netherlands	1
Czech Republic\|United States\|Australia\|Bulgaria\|Canada\|France\|Germany\|Greece\|Hungary\|India\|Italy\|Korea, Republic of\|Latvia\|Malaysia\|Philippines\|Poland\|Romania\|Russian Federation\|Singapore\|Spain\|Taiwan\|Turkey\|United Kingdom	1
Denmark\|France\|Germany\|Italy\|Korea, Republic of\|Netherlands\|Spain\|Taiwan\|United Kingdom	1
Denmark\|Germany\|Italy\|Spain\|Sweden	1
Denmark\|United Kingdom	1
Egypt	1
Egypt\|Estonia\|Argentina\|Australia\|Austria\|Bosnia and Herzegovina\|Brazil\|Canada\|China\|Colombia\|Czech Republic\|Denmark\|Ecuador\|Finland\|France\|Germany\|Hong Kong\|Hungary\|Iceland\|Israel\|Italy\|Latvia\|Lebanon\|Lithuania\|Mexico\|Netherlands\|Poland\|Portugal\|Romania\|Russian Federation\|Serbia\|Slovakia\|Slovenia\|Spain\|Sweden\|Switzerland\|Taiwan\|Turkey\|United Kingdom\|Venezuela	1
Egypt\|Lebanon\|Saudi Arabia	1
Egypt\|Malaysia\|Philippines\|Poland\|Romania\|Serbia\|Thailand	1
Finland\|Germany\|Italy\|Netherlands\|United Kingdom	1
France\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Bulgaria\|Chile\|Czech Republic\|Germany\|Hong Kong\|Hungary\|Ireland\|Italy\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Russian Federation\|Singapore\|Slovakia\|Spain\|Sweden\|Switzerland\|Taiwan\|Turkey\|Ukraine\|United Kingdom	1
France\|Czechia\|Germany\|Greece\|Italy\|Poland\|Romania\|Spain	1
France\|Germany\|Greece\|Italy\|Korea, Republic of\|Netherlands\|Russian Federation\|Spain\|Sweden\|Switzerland\|Turkey\|United Arab Emirates	1
France\|Germany\|Hungary\|Poland	1
France\|Germany\|Italy\|Netherlands\|Spain\|United Kingdom	1
France\|Germany\|Italy\|Spain	1
France\|Germany\|Italy\|Spain\|United Kingdom	1
France\|Germany\|Spain	1
France\|Italy\|Spain	1
France\|Jordan\|Poland\|Slovenia\|Spain	1
France\|Korea, Republic of\|Spain	1
France\|Korea, Republic of\|Spain\|United Kingdom	1
France\|Switzerland\|United Kingdom	1
France\|United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|China\|Czechia\|Germany\|Ireland\|Italy\|Japan\|Mexico\|Netherlands\|Poland\|Puerto Rico\|Romania\|Russian Federation\|Spain\|Taiwan\|United Kingdom	1
France\|United States\|Spain\|United Kingdom	1
Georgia	1
Germany\|Italy	1
Germany\|Italy\|Netherlands\|Poland\|United Kingdom	1
Germany\|Italy\|Poland\|United Kingdom	1
Germany\|Netherlands\|Spain\|Switzerland	1
Germany\|Poland	1
Germany\|Spain	1
Germany\|United Kingdom	1
Germany\|United States\|Argentina\|Belgium\|Brazil\|Canada\|China\|Croatia\|Denmark\|Estonia\|France\|Hong Kong\|Indonesia\|Italy\|Latvia\|Malaysia\|Mexico\|Philippines\|Singapore\|Slovenia\|Spain\|Sweden\|Switzerland\|Thailand\|Turkey	1
Germany\|United States\|Argentina\|France\|Israel\|Italy\|Latvia\|Spain\|United Kingdom	1
Germany\|United States\|Austria	1
Germany\|United States\|Canada	1
Greece\|Australia\|Belarus\|Brazil\|Bulgaria\|Chile\|China\|Colombia\|Czechia\|Georgia\|Hungary\|Jordan\|Lebanon\|Malaysia\|Mexico\|Philippines\|Poland\|Romania\|Russian Federation\|Spain\|Taiwan\|Thailand\|Turkey\|Ukraine	1
Greece\|Germany\|Australia\|Austria\|Belgium\|Canada\|Czech Republic\|Estonia\|Finland\|France\|Hong Kong\|Hungary\|Italy\|Poland\|Spain	1
Hong Kong\|India\|China\|Korea, Republic of\|Mexico\|Philippines\|Poland\|Russian Federation\|Taiwan\|Turkey	1
Hong Kong\|Korea, Republic of\|Malaysia\|Philippines\|Singapore\|Taiwan\|Thailand	1
Hong Kong\|Korea, Republic of\|Malaysia\|Singapore\|Taiwan\|Thailand	1
Hong Kong\|Korea, Republic of\|Taiwan\|Thailand	1
Hungary\|Poland\|Russian Federation	1
Hungary\|Serbia\|Spain	1
Hungary\|United States\|Austria\|France\|Italy\|Poland\|Romania\|Spain	1
Hungary\|United States\|Belgium\|Czechia\|Italy\|Korea, Republic of\|United Kingdom	1
Ireland	1
Ireland\|Korea, Republic of\|Netherlands\|Singapore\|Spain\|Switzerland	1
Ireland\|United Kingdom	1
Israel\|Italy\|Japan\|United States\|Belgium\|Canada\|China\|France\|Germany\|Korea, Republic of\|Netherlands\|Poland\|Spain\|United Kingdom	1
Italy\|Netherlands\|Poland\|South Africa\|United Kingdom	1
Italy\|Netherlands\|Spain\|United Kingdom	1
Italy\|United States\|Argentina\|Australia\|Austria\|Canada\|Chile\|Czechia\|France\|Germany\|Hungary\|Ireland\|Mexico\|Netherlands\|Peru\|Poland\|Romania\|Russian Federation\|Spain\|United Kingdom	1
Italy\|United States\|France\|Germany\|India\|Poland\|Russian Federation\|Ukraine	1
Japan\|Brazil\|Czechia\|Hungary\|India\|Korea, Republic of\|Mexico\|Peru\|Philippines\|Poland\|Russian Federation\|Thailand\|Turkey\|Vietnam	1
Japan\|Korea, Republic of\|Singapore\|Taiwan	1
Japan\|Korea, Republic of\|Taiwan	1
Japan\|United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|Chile\|China\|France\|Germany\|Ireland\|Italy\|Mexico\|Poland\|Romania\|Russian Federation\|Spain\|United Kingdom	1
Japan\|United States\|Argentina\|Brazil\|China\|Hungary\|India\|Korea, Republic of\|Malaysia\|Peru\|Russian Federation\|Spain\|Taiwan\|Thailand\|Turkey\|Vietnam	1
Jordan\|Lebanon	1
Kazakhstan\|Russian Federation	1
Korea, Republic of\|Poland	1
Mexico\|United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Canada\|Chile\|Czechia\|Denmark\|France\|Germany\|Hungary\|Italy\|Netherlands\|Peru\|Poland\|Romania\|Russian Federation\|Spain\|Sweden\|United Kingdom	1
Netherlands\|Spain\|Switzerland	1
Netherlands\|United Kingdom	1
Peru\|United States\|Argentina\|Australia\|Brazil\|Canada\|Italy\|Korea, Republic of\|New Zealand\|Philippines\|Taiwan\|Thailand	1
Poland\|Albania\|Argentina\|Australia\|Austria\|Belgium\|Bosnia and Herzegovina\|Brazil\|Bulgaria\|Chile\|China\|Colombia\|Croatia\|Czech Republic\|Ecuador\|Egypt\|Estonia\|Finland\|Germany\|Greece\|Guatemala\|Hong Kong\|Hungary\|India\|Indonesia\|Ireland\|Israel\|Italy\|Korea, Republic of\|Latvia\|Lithuania\|Malaysia\|Mexico\|Netherlands\|New Zealand\|Panama\|Peru\|Portugal\|Romania\|Russian Federation\|Saudi Arabia\|Serbia\|Slovakia\|Slovenia\|Sweden\|Switzerland\|Taiwan\|Thailand\|Turkey\|Uruguay\|Venezuela	1
Poland\|Romania\|South Africa\|Ukraine	1
Poland\|Russian Federation\|United States\|Australia\|France\|Germany\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Singapore\|Spain\|Taiwan\|United Kingdom	1
Poland\|Spain\|China\|Hong Kong\|Italy\|Japan\|Korea, Republic of	1
Poland\|Spain\|United States\|France\|Italy\|Japan	1
Poland\|United States\|Belarus\|Bosnia and Herzegovina\|Bulgaria\|Croatia\|Georgia\|Germany\|Greece\|Hungary\|Italy\|Japan\|Korea, Republic of\|Peru\|Philippines\|Romania\|Russian Federation\|Serbia\|Spain\|Taiwan\|Thailand\|Turkey\|Ukraine\|Vietnam	1
Portugal	1
Romania\|Australia\|Austria\|Belgium\|Canada\|Chile\|China\|Czech Republic\|Denmark\|France\|Germany\|Greece\|Hungary\|Italy\|Korea, Republic of\|Lithuania\|Malaysia\|Netherlands\|New Zealand\|Poland\|Russian Federation\|Slovakia\|Slovenia\|South Africa\|Spain\|Ukraine\|United Kingdom\|Venezuela	1
Russian Federation\|Taiwan\|United States\|Austria\|Belgium\|Korea, Republic of\|Poland\|Thailand	1
Russian Federation\|Ukraine	1
Serbia	1
Slovakia\|United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Bulgaria\|Canada\|Chile\|France\|Germany\|Israel\|Italy\|Japan\|Latvia\|Lithuania\|Mexico\|Netherlands\|Peru\|Portugal\|Russian Federation\|Singapore\|Spain\|Taiwan\|Ukraine	1
Spain\|Austria\|Belgium\|Brazil\|Canada\|China\|Cyprus\|Finland\|France\|Germany\|Greece\|Hungary\|Israel\|Italy\|Mexico\|Netherlands\|Switzerland\|United Kingdom	1
Spain\|Taiwan\|United States\|Argentina\|France\|Germany\|Israel\|Italy\|Latvia\|Malaysia\|Mexico\|Philippines\|United Kingdom	1
Spain\|United States\|Argentina\|Australia\|Austria\|Brazil\|Canada\|Chile\|China\|Colombia\|Czechia\|Denmark\|Finland\|France\|Germany\|Greece\|Hong Kong\|Hungary\|Iceland\|India\|Italy\|Japan\|Korea, Republic of\|Lebanon\|Malaysia\|Netherlands\|Norway\|Philippines\|Poland\|Portugal\|Romania\|Russian Federation\|Singapore\|Slovakia\|South Africa\|Sweden\|Switzerland\|Taiwan\|Thailand\|Turkey\|United Kingdom\|Vietnam	1
Spain\|United States\|Canada\|Germany\|Korea, Republic of\|Taiwan	1
Sweden\|United Kingdom	1
Turkey\|United States\|Australia\|Belgium\|Brazil\|Canada\|France\|Germany\|Hong Kong\|Italy\|Korea, Republic of\|Netherlands\|Russian Federation\|Singapore\|Spain\|Taiwan\|United Kingdom	1
Ukraine\|United Kingdom\|United States\|Belgium\|Hungary\|India\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Russian Federation	1
Ukraine\|United States\|Belarus\|Belgium\|Canada\|Czechia\|France\|Germany\|Hungary\|Italy\|Netherlands\|Poland\|Russian Federation\|Serbia\|Slovenia\|Spain	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Bulgaria\|Canada\|Chile\|France\|Germany\|Hungary\|Israel\|Italy\|Mexico\|Netherlands\|Peru\|Poland\|Portugal\|Romania\|Russian Federation\|Spain\|Sweden\|Turkey\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Bulgaria\|Canada\|Chile\|France\|Germany\|Italy\|Japan\|Latvia\|Lithuania\|Mexico\|Netherlands\|Peru\|Portugal\|Russian Federation\|Singapore\|Slovakia\|Spain\|Switzerland\|Taiwan\|Ukraine	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Canada\|Chile\|China\|Colombia\|Czechia\|Finland\|France\|Germany\|Greece\|Hungary\|Ireland\|Israel\|Italy\|Japan\|Korea, Republic of\|Lebanon\|Mexico\|Netherlands\|Peru\|Poland\|Romania\|Russian Federation\|Saudi Arabia\|South Africa\|Spain\|Switzerland\|Taiwan\|Turkey\|United Arab Emirates\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Canada\|Chile\|France\|Germany\|Hong Kong\|Hungary\|Ireland\|Italy\|Japan\|Korea, Republic of\|Malaysia\|Peru\|Philippines\|Romania\|Russian Federation\|Taiwan\|Thailand\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Canada\|Czechia\|Finland\|France\|Germany\|Greece\|Hungary\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Romania\|Spain\|Sweden\|Switzerland\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Canada\|Denmark\|Finland\|France\|Germany\|Greece\|Hungary\|India\|Israel\|Italy\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Portugal\|Puerto Rico\|Spain\|Sweden\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Chile\|Colombia\|Czech Republic\|Egypt\|Former Yugoslavia\|France\|Greece\|Israel\|Italy\|Japan\|Lithuania\|Macedonia, The Former Yugoslav Republic of\|Morocco\|Norway\|Philippines\|Poland\|Portugal\|Slovenia\|South Africa\|Spain\|Sweden\|Switzerland\|Tunisia	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Bulgaria\|Chile\|China\|France\|Hungary\|Ireland\|Israel\|Italy\|Japan\|Korea, Republic of\|Latvia\|Lithuania\|Malaysia\|Netherlands\|Peru\|Portugal\|Romania\|Russian Federation\|Spain\|Taiwan\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Canada\|China\|France\|Germany\|Hong Kong\|Israel\|Italy\|Korea, Republic of\|Mexico\|Netherlands\|Peru\|Philippines\|Singapore\|Spain\|Taiwan\|Thailand\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Belgium\|Canada\|Czech Republic\|France\|Germany\|Greece\|Hungary\|Italy\|Korea, Republic of\|Poland\|Romania\|Russian Federation\|Spain\|Taiwan\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Brazil\|Bulgaria\|Canada\|Chile\|China\|Czech Republic\|Estonia\|Finland\|France\|Germany\|Greece\|Hong Kong\|Hungary\|India\|Italy\|Korea, Republic of\|Malaysia\|Netherlands\|Poland\|Portugal\|Romania\|Russian Federation\|Singapore\|Spain\|Sweden\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Brazil\|Canada\|Chile\|Czechia\|France\|Germany\|Hong Kong\|Hungary\|Italy\|Mexico\|Norway\|Peru\|Poland\|Romania\|Russian Federation\|Singapore\|Spain\|Switzerland	1
United States\|Argentina\|Australia\|Austria\|Brazil\|Canada\|Colombia\|France\|Germany\|Japan\|Korea, Republic of\|New Zealand\|Poland\|Romania\|Russian Federation\|Spain\|Taiwan\|Turkey\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Brazil\|Canada\|France\|Germany\|Hungary\|Italy\|Japan\|Korea, Republic of\|New Zealand\|Norway\|Poland\|Russian Federation\|Spain\|Switzerland\|Turkey\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Austria\|Brazil\|Denmark\|France\|Germany\|Greece\|Hungary\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Peru\|Poland\|Russian Federation\|Serbia\|Spain\|Switzerland\|Taiwan\|Thailand\|Turkey\|Ukraine	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Bulgaria\|Chile\|Colombia\|Croatia\|Czechia\|Denmark\|France\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Mexico\|Peru\|Poland\|Romania\|Russian Federation\|Slovakia\|South Africa\|Spain\|Switzerland\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Bulgaria\|Hong Kong\|Israel\|Italy\|Mexico\|Philippines\|Romania\|Singapore\|Spain\|Taiwan\|Thailand\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|Chile\|Costa Rica\|France\|Germany\|Hong Kong\|Israel\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|New Zealand\|Panama\|Peru\|Poland\|Russian Federation\|Serbia\|Singapore\|Spain\|Taiwan\|Thailand\|Turkey	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|Chile\|Croatia\|France\|Germany\|Hong Kong\|Hungary\|Ireland\|Israel\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Peru\|Poland\|Russian Federation\|Serbia\|South Africa\|Spain\|Taiwan\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|Chile\|France\|Germany\|Greece\|Ireland\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Puerto Rico\|Romania\|Spain\|Sweden\|Switzerland\|Taiwan\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|China\|Czechia\|France\|Germany\|Greece\|Hong Kong\|Israel\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Romania\|Russian Federation\|Singapore\|Spain\|Taiwan\|Turkey\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|China\|Czechia\|France\|Germany\|Hong Kong\|Israel\|Italy\|Korea, Republic of\|Netherlands\|Peru\|Poland\|Russian Federation\|Spain\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|China\|France\|Germany\|Greece\|India\|Ireland\|Korea, Republic of\|Netherlands\|Portugal\|Spain\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|Colombia\|France\|Germany\|Hong Kong\|Korea, Republic of\|Mexico\|Philippines\|Singapore\|Spain\|Taiwan\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Brazil\|Canada\|Czechia\|Japan\|Korea, Republic of\|Netherlands\|Spain\|Taiwan	1
United States\|Argentina\|Australia\|Belgium\|Bulgaria\|Canada\|Chile\|China\|France\|Hungary\|Japan\|Korea, Republic of\|Netherlands\|Poland\|Russian Federation\|Spain\|Turkey	1
United States\|Argentina\|Australia\|Belgium\|Canada\|China\|Czechia\|France\|Germany\|Hong Kong\|India\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Russian Federation\|Singapore\|Spain\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|Belgium\|Colombia\|France\|Germany\|Greece\|Hong Kong\|India\|Israel\|Italy\|Mexico\|Philippines\|Portugal\|South Africa\|Spain\|Sweden\|Taiwan\|United Kingdom\|Venezuela	1
United States\|Argentina\|Australia\|Bosnia and Herzegovina\|Brazil\|Canada\|Chile\|Colombia\|Ecuador\|Germany\|Hong Kong\|Hungary\|Ireland\|Korea, Republic of\|Latvia\|Macedonia, The Former Yugoslav Republic of\|Malaysia\|Mexico\|Moldova, Republic of\|Netherlands\|New Zealand\|Panama\|Peru\|Philippines\|Poland\|Romania\|Serbia\|Sweden\|Taiwan\|Thailand\|Turkey\|Ukraine	1
United States\|Argentina\|Australia\|Brazil\|Canada\|Chile\|China\|Germany\|Greece\|Israel\|Mexico\|New Zealand\|Romania\|Singapore\|South Africa\|Sweden\|Thailand	1
United States\|Argentina\|Australia\|Brazil\|Canada\|Chile\|Colombia\|France\|Germany\|Hungary\|Ireland\|Italy\|Korea, Republic of\|Latvia\|Mexico\|Peru\|Poland\|South Africa\|Spain\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Brazil\|Canada\|Chile\|France\|Germany\|Hungary\|Israel\|Italy\|Netherlands\|Russian Federation\|Spain\|Ukraine\|United Kingdom	1
United States\|Argentina\|Australia\|Brazil\|Canada\|China\|Czechia\|India\|Japan\|Korea, Republic of\|Peru\|Philippines\|Russian Federation\|Slovakia\|South Africa\|Taiwan\|Thailand\|United Kingdom\|Vietnam	1
United States\|Argentina\|Australia\|Brazil\|Canada\|China\|Denmark\|France\|Germany\|Hong Kong\|India\|Indonesia\|Italy\|Korea, Republic of\|Mexico\|Netherlands\|Norway\|Philippines\|Spain\|Taiwan\|Thailand\|United Kingdom	1
United States\|Argentina\|Australia\|Brazil\|Chile\|India	1
United States\|Argentina\|Australia\|Canada\|Czechia\|Denmark\|Finland\|Germany\|Hungary\|Israel\|Japan\|Korea, Republic of\|Netherlands\|New Zealand\|Russian Federation\|South Africa\|Spain\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Australia\|France\|Germany\|Italy\|Korea, Republic of\|Russian Federation\|Spain\|Taiwan	1
United States\|Argentina\|Austria\|Belgium\|Brazil\|Bulgaria\|Canada\|Chile\|China\|France\|Germany\|Greece\|Hong Kong\|Hungary\|India\|Indonesia\|Israel\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Pakistan\|Peru\|Philippines\|Poland\|Russian Federation\|Singapore\|South Africa\|Spain\|Sweden\|Taiwan\|Thailand\|Turkey\|United Kingdom	1
United States\|Argentina\|Austria\|Belgium\|Brazil\|Bulgaria\|Canada\|Chile\|China\|France\|Germany\|Hungary\|India\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Peru\|Philippines\|Romania\|Russian Federation\|Spain\|Taiwan\|Thailand\|Vietnam	1
United States\|Argentina\|Austria\|Belgium\|Brazil\|Canada\|China\|Denmark\|France\|Germany\|Greece\|India\|Indonesia\|Italy\|Japan\|Korea, Republic of\|Malaysia\|Mexico\|Netherlands\|Portugal\|Singapore\|Spain\|Thailand\|Turkey\|Vietnam	1
United States\|Argentina\|Austria\|Belgium\|Brazil\|Canada\|France\|Germany\|Israel\|Italy\|Japan\|Korea, Republic of\|Lebanon\|Mexico\|Netherlands\|Norway\|Poland\|Russian Federation\|Singapore\|Spain\|Sweden\|Switzerland\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Austria\|Belgium\|Brazil\|Denmark\|France\|Germany\|Greece\|Italy\|Japan\|Lebanon\|Mexico\|Netherlands\|Oman\|Slovakia\|Spain\|United Arab Emirates	1
United States\|Argentina\|Austria\|Brazil\|Bulgaria\|Canada\|Chile\|China\|Colombia\|Czechia\|France\|Germany\|Greece\|Guatemala\|Hong Kong\|Hungary\|Iceland\|India\|Israel\|Italy\|Japan\|Jordan\|Korea, Republic of\|Lebanon\|Malaysia\|Mexico\|Norway\|Panama\|Peru\|Philippines\|Poland\|Portugal\|Romania\|Russian Federation\|South Africa\|Spain\|Switzerland\|Taiwan\|Thailand\|Turkey\|United Kingdom\|Vietnam	1
United States\|Argentina\|Austria\|Brazil\|Canada\|Chile\|Finland\|France\|Germany\|Greece\|Guatemala\|Hungary\|Italy\|Japan\|Korea, Republic of\|Netherlands\|New Zealand\|Norway\|Panama\|Poland\|Portugal\|Russian Federation\|Serbia\|Spain\|Sweden\|Switzerland\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
United States\|Argentina\|Austria\|Brazil\|Canada\|France\|Germany\|Greece\|Hungary\|India\|Israel\|Italy\|Korea, Republic of\|Mexico\|Netherlands\|New Zealand\|Norway\|Poland\|Puerto Rico\|Romania\|Russian Federation\|Spain\|Sweden\|Switzerland\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Austria\|Canada\|Chile\|China\|Croatia\|France\|Germany\|Greece\|Hong Kong\|Italy\|Korea, Republic of\|Mexico\|Romania\|Russian Federation\|Spain\|Sweden\|Taiwan\|Thailand	1
United States\|Argentina\|Austria\|Canada\|Chile\|China\|Denmark\|France\|Germany\|Greece\|Hungary\|India\|Ireland\|Italy\|Korea, Republic of\|Mexico\|Netherlands\|Portugal\|Singapore\|Spain\|Taiwan\|Turkey\|United Kingdom	1
United States\|Argentina\|Belgium\|Brazil\|Canada\|China\|France\|Germany\|Greece\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Spain\|Taiwan\|Turkey\|Ukraine	1
United States\|Argentina\|Belgium\|Brazil\|Canada\|China\|France\|Germany\|Ireland\|Italy\|Japan\|Korea, Republic of\|Poland\|Romania\|Russian Federation\|South Africa\|Spain\|Taiwan\|Ukraine\|United Kingdom	1
United States\|Argentina\|Belgium\|Brazil\|Canada\|France\|Germany\|Hong Kong\|Hungary\|Italy\|Japan\|Netherlands\|Singapore\|Spain\|Taiwan\|Thailand\|Turkey\|United Kingdom	1
United States\|Argentina\|Belgium\|Brazil\|Canada\|France\|Germany\|Israel\|Italy\|Netherlands\|Spain\|Turkey	1
United States\|Argentina\|Belgium\|Germany\|South Africa\|United Kingdom	1
United States\|Argentina\|Brazil\|Bulgaria\|Chile\|China\|Denmark\|Finland\|Greece\|Hong Kong\|India\|Israel\|Japan\|Korea, Republic of\|Malaysia\|Mexico\|Peru\|Philippines\|Poland\|Portugal\|Qatar\|Romania\|Russian Federation\|Saudi Arabia\|Singapore\|Sweden\|Turkey\|Ukraine\|United Kingdom	1
United States\|Argentina\|Brazil\|Bulgaria\|Chile\|Colombia\|Greece\|Hungary\|Mexico\|Peru\|Poland\|Romania\|Russian Federation\|Spain\|Turkey\|Ukraine	1
United States\|Argentina\|Brazil\|Bulgaria\|Chile\|Croatia\|Egypt\|Germany\|Greece\|Hungary\|Italy\|Japan\|Korea, Republic of\|Malaysia\|Mexico\|Philippines\|Poland\|Portugal\|Romania\|Russian Federation\|Serbia\|South Africa\|Spain\|Thailand\|Turkey\|Ukraine\|United Kingdom\|Vietnam	1
United States\|Argentina\|Brazil\|Canada\|China\|France\|Greece\|Hungary\|Italy\|Japan\|Korea, Republic of\|Romania\|Spain\|Taiwan\|Turkey	1
United States\|Argentina\|Brazil\|Czech Republic\|Hungary\|India	1
United States\|Argentina\|Canada\|France\|Korea, Republic of\|Poland\|Spain\|Taiwan	1
United States\|Argentina\|China\|Korea, Republic of	1
United States\|Argentina\|France\|Hungary\|Spain\|Thailand	1
United States\|Australia\|Austria\|Belarus\|Bosnia and Herzegovina\|China\|Denmark\|Egypt\|France\|Germany\|Greece\|Hungary\|Israel\|Italy\|Japan\|Kazakhstan\|Korea, Republic of\|Latvia\|Lebanon\|North Macedonia\|Poland\|Portugal\|Romania\|Russian Federation\|Saudi Arabia\|Singapore\|South Africa\|Spain\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
United States\|Australia\|Austria\|Belgium\|Brazil\|Bulgaria\|Canada\|Colombia\|Czechia\|Germany\|Greece\|India\|Italy\|Korea, Republic of\|Lebanon\|Malaysia\|Netherlands\|Poland\|Russian Federation\|Spain\|Taiwan\|Thailand\|Turkey\|United Kingdom	1
United States\|Australia\|Austria\|Belgium\|Brazil\|Canada\|Croatia\|France\|Germany\|Greece\|Hungary\|Italy\|Korea, Republic of\|Philippines\|Poland\|Portugal\|Romania\|Russian Federation\|Serbia\|Singapore\|Slovakia\|South Africa\|Spain\|Taiwan\|Thailand\|United Kingdom	1
United States\|Australia\|Austria\|Belgium\|Brazil\|Canada\|Croatia\|France\|Germany\|Greece\|Hungary\|Italy\|Poland\|Portugal\|Romania\|Russian Federation\|Slovakia\|South Africa\|Spain\|United Kingdom	1
United States\|Australia\|Austria\|Belgium\|Canada\|France\|Germany\|Netherlands	1
United States\|Australia\|Austria\|Belgium\|Canada\|France\|Israel\|Italy\|Spain	1
United States\|Australia\|Austria\|Brazil\|Bulgaria\|China\|Croatia\|Czech Republic\|Germany\|Greece\|Hungary\|India\|Italy\|Korea, Republic of\|Netherlands\|Poland\|Romania\|Spain\|Taiwan\|Turkey	1
United States\|Australia\|Austria\|Brazil\|China\|France\|Germany\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Poland\|Russian Federation\|Serbia\|Slovenia\|South Africa\|Spain\|Sweden\|Switzerland\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
United States\|Australia\|Austria\|Canada\|China\|France\|Germany\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Spain\|Sweden\|Taiwan	1
United States\|Australia\|Austria\|Canada\|Denmark\|France\|Germany\|Hong Kong\|Italy\|Korea, Republic of\|Luxembourg\|Netherlands\|Norway\|Singapore\|Spain\|Sweden\|Switzerland\|Taiwan\|United Kingdom	1
United States\|Australia\|Austria\|Canada\|France\|Italy\|Spain\|Switzerland	1
United States\|Australia\|Belarus\|Belgium\|Canada\|Czechia\|France\|Germany\|Hungary\|Israel\|Italy\|Poland\|Russian Federation\|Serbia\|Slovenia\|Spain\|Ukraine	1
United States\|Australia\|Belgium\|Bosnia and Herzegovina\|Bulgaria\|Canada\|France\|Georgia\|Germany\|Hong Kong\|Italy\|Japan\|Netherlands\|Singapore\|Slovenia\|Spain\|Switzerland\|Turkey\|United Kingdom	1
United States\|Australia\|Belgium\|Brazil\|Bulgaria\|Canada\|Chile\|China\|Colombia\|Croatia\|Cyprus\|Czechia\|Denmark\|Estonia\|France\|Germany\|Greece\|Hungary\|Ireland\|Israel\|Italy\|Japan\|Korea, Republic of\|Lebanon\|Lithuania\|Netherlands\|New Zealand\|Peru\|Poland\|Portugal\|Romania\|Russian Federation\|Serbia\|Singapore\|Slovakia\|South Africa\|Spain\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
United States\|Australia\|Belgium\|Canada\|Chile\|France\|Germany\|Greece\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Mexico\|Netherlands\|Peru\|Poland\|Singapore\|Slovakia\|South Africa\|Spain\|Taiwan\|Thailand\|Turkey\|United Kingdom\|Vietnam	1
United States\|Australia\|Belgium\|Canada\|China\|France\|Germany\|Greece\|Hungary\|Ireland\|Israel\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Puerto Rico\|Romania\|Russian Federation\|Spain\|Taiwan\|Turkey\|United Kingdom	1
United States\|Australia\|Belgium\|Canada\|France\|Germany\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Singapore\|Spain\|Switzerland\|Taiwan	1
United States\|Australia\|Belgium\|Canada\|France\|Germany\|Hungary\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Russian Federation\|Spain\|Switzerland\|Taiwan\|Thailand\|Vietnam	1
United States\|Australia\|Belgium\|Canada\|France\|Germany\|Ireland\|Italy\|Poland\|Spain\|United Kingdom	1
United States\|Australia\|Belgium\|Canada\|France\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|New Zealand\|Norway\|Russian Federation\|Singapore\|Spain\|Sweden\|Taiwan\|Thailand\|United Kingdom	1
United States\|Australia\|Belgium\|Canada\|Germany\|Spain	1
United States\|Australia\|Belgium\|Canada\|Greece\|Spain	1
United States\|Australia\|Belgium\|Canada\|Hong Kong\|Italy\|Netherlands\|Singapore\|Spain	1
United States\|Australia\|Belgium\|China\|France\|Germany\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Poland\|Singapore\|Spain\|Taiwan\|United Kingdom	1
United States\|Australia\|Belgium\|Croatia\|Poland\|Romania\|Russian Federation	1
United States\|Australia\|Belgium\|Denmark\|France\|Germany\|Italy\|Korea, Republic of\|Luxembourg\|Netherlands\|Russian Federation\|Singapore\|Spain\|Sweden\|Taiwan\|United Kingdom	1
United States\|Australia\|Belgium\|France\|Germany\|Greece\|Hungary\|Italy\|Korea, Republic of\|Romania\|Russian Federation\|Spain\|Taiwan\|Ukraine	1
United States\|Australia\|Belgium\|France\|Germany\|Italy\|Korea, Republic of\|Poland\|Spain\|Sweden	1
United States\|Australia\|Belgium\|France\|Italy\|Korea, Republic of\|Spain\|Taiwan\|United Kingdom	1
United States\|Australia\|Belgium\|Greece\|Japan\|Korea, Republic of\|Netherlands	1
United States\|Australia\|Bosnia and Herzegovina\|Brazil\|Canada\|Chile\|China\|Costa Rica\|Egypt\|France\|Germany\|Guatemala\|Hong Kong\|Israel\|Italy\|Korea, Republic of\|Mexico\|New Zealand\|Poland\|Portugal\|Russian Federation\|Serbia\|Singapore\|Spain\|Switzerland\|Taiwan\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
United States\|Australia\|Brazil\|Bulgaria\|Chile\|Croatia\|Czechia\|France\|Germany\|Greece\|Hungary\|India\|Italy\|Japan\|Korea, Republic of\|Malaysia\|Netherlands\|Philippines\|Poland\|Romania\|Russian Federation\|South Africa\|Spain\|Taiwan\|Thailand\|Turkey\|Ukraine	1
United States\|Australia\|Brazil\|Canada\|China\|France\|Germany\|Hong Kong\|Israel\|Italy\|Japan\|Korea, Republic of\|Mexico\|Spain\|Sweden\|Taiwan\|United Kingdom	1
United States\|Australia\|Brazil\|Canada\|Hong Kong\|Korea, Republic of\|Poland\|Puerto Rico\|Singapore\|Spain\|Taiwan\|United Kingdom	1
United States\|Australia\|Brazil\|Czech Republic\|Russian Federation\|Singapore	1
United States\|Australia\|Brazil\|France\|Bulgaria\|Canada\|China\|Hungary\|Italy\|Japan\|Korea, Republic of\|Netherlands\|New Zealand\|Poland\|Romania\|Singapore\|Spain\|Taiwan\|Ukraine	1
United States\|Australia\|Bulgaria	1
United States\|Australia\|Canada\|China\|Colombia\|Estonia\|France\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Malaysia\|Mexico\|Poland\|Russian Federation\|Taiwan\|Turkey\|Ukraine	1
United States\|Australia\|Canada\|China\|France\|Italy\|Japan\|Korea, Republic of\|Spain\|Taiwan\|United Kingdom	1
United States\|Australia\|Canada\|Colombia\|France\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Puerto Rico\|Russian Federation\|Spain\|United Kingdom	1
United States\|Australia\|Canada\|Czech Republic\|France\|Greece\|Hungary\|Israel\|Poland\|Russian Federation\|United Kingdom	1
United States\|Australia\|Canada\|Czechia\|France\|Germany\|Greece\|Italy\|Netherlands\|United Kingdom	1
United States\|Australia\|Canada\|Czechia\|Hungary\|Italy\|Spain\|United Kingdom	1
United States\|Australia\|Canada\|Denmark\|Estonia\|Ireland\|Israel\|Italy\|Japan\|Korea, Republic of\|Malaysia\|Poland\|Russian Federation\|Spain\|Switzerland\|Turkey\|Ukraine\|United Kingdom	1
United States\|Australia\|Canada\|Denmark\|France\|Germany\|Hong Kong\|Israel\|Italy\|Japan\|Korea, Republic of\|Singapore\|Spain\|Switzerland\|Taiwan\|United Kingdom	1
United States\|Australia\|Canada\|Finland\|France\|Germany\|Italy\|Norway\|Poland\|Spain\|Sweden	1
United States\|Australia\|Canada\|France\|Germany\|Italy\|Korea, Republic of\|Norway\|Singapore\|Spain\|Taiwan	1
United States\|Australia\|Canada\|Hong Kong\|Ireland\|Italy\|Japan\|Korea, Republic of\|Poland\|Russian Federation\|Singapore\|South Africa\|Spain\|Switzerland\|Taiwan\|United Kingdom	1
United States\|Australia\|Canada\|Hungary\|Ireland\|Israel\|Italy\|Korea, Republic of\|Mexico\|Russian Federation\|Spain\|Taiwan\|Turkey\|United Kingdom	1
United States\|Australia\|Canada\|Hungary\|Italy\|Korea, Republic of\|Poland\|Taiwan\|United Kingdom	1
United States\|Australia\|Canada\|Israel\|Korea, Republic of	1
United States\|Australia\|Chile\|Croatia\|France\|Germany\|Italy\|Korea, Republic of\|Poland\|Romania\|Russian Federation\|Serbia\|Ukraine	1
United States\|Australia\|China	1
United States\|Australia\|China\|Hungary\|Korea, Republic of\|Netherlands\|Poland\|Russian Federation\|Taiwan\|Thailand\|Turkey\|Vietnam	1
United States\|Australia\|Czech Republic\|France\|Germany\|Hungary\|Poland	1
United States\|Australia\|France\|Germany\|Hungary\|Italy\|Korea, Republic of\|Poland\|Romania\|Russian Federation\|Spain\|Taiwan\|Ukraine	1
United States\|Australia\|France\|Germany\|Italy\|Japan\|Korea, Republic of\|Spain\|Taiwan\|United Kingdom	1
United States\|Australia\|France\|Germany\|Italy\|Netherlands\|Singapore\|Spain\|Switzerland	1
United States\|Australia\|France\|Germany\|Korea, Republic of\|New Zealand\|Poland\|Russian Federation\|Spain\|United Kingdom	1
United States\|Australia\|France\|Germany\|Korea, Republic of\|Spain\|Taiwan	1
United States\|Australia\|France\|Israel\|Korea, Republic of\|Spain\|United Kingdom	1
United States\|Australia\|France\|Italy\|Japan	1
United States\|Australia\|Germany	1
United States\|Australia\|Germany\|Italy\|United Kingdom	1
United States\|Australia\|Hong Kong\|Korea, Republic of\|Singapore\|Taiwan	1
United States\|Australia\|Hungary\|Israel\|Poland\|Russian Federation\|United Kingdom	1
United States\|Australia\|Italy\|Singapore\|Spain	1
United States\|Australia\|Japan\|Korea, Republic of\|Spain	1
United States\|Australia\|New Zealand\|Poland\|Thailand	1
United States\|Australia\|Puerto Rico\|South Africa	1
United States\|Australia\|Spain\|United Kingdom	1
United States\|Austria\|Belgium\|Bulgaria\|Germany\|Hungary\|Israel\|Italy\|Lithuania\|Romania\|Slovenia\|Ukraine\|United Kingdom	1
United States\|Austria\|Belgium\|Canada\|Czechia\|France\|Germany\|Hungary\|Italy\|Japan\|Korea, Republic of\|Philippines\|Poland\|Singapore\|Spain\|Taiwan\|Thailand\|United Kingdom	1
United States\|Austria\|Belgium\|Canada\|Czechia\|France\|Germany\|Italy\|Netherlands\|Poland\|Spain\|Switzerland	1
United States\|Austria\|Belgium\|Canada\|Finland\|France\|Germany\|Italy\|Netherlands\|Poland\|Portugal\|Spain\|Switzerland\|United Kingdom	1
United States\|Austria\|Belgium\|China\|Denmark\|Finland\|France\|Germany\|Greece\|Hungary\|India\|Ireland\|Japan\|Korea, Republic of\|Mexico\|Poland\|Russian Federation\|Slovakia\|South Africa\|Spain\|Sweden\|Switzerland\|United Kingdom	1
United States\|Austria\|Belgium\|China\|Greece\|Korea, Republic of\|Portugal\|Spain\|Ukraine	1
United States\|Austria\|Belgium\|France\|Germany\|Israel\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Poland\|Spain\|Switzerland\|Taiwan	1
United States\|Austria\|Canada\|France\|Germany\|Israel\|Italy\|Poland\|Spain	1
United States\|Austria\|Canada\|France\|Germany\|Israel\|Korea, Republic of	1
United States\|Austria\|Canada\|France\|Germany\|Spain	1
United States\|Austria\|Canada\|Germany\|Hungary\|Ireland\|Italy\|Portugal	1
United States\|Austria\|China\|Czechia\|France\|Georgia\|Greece\|Ireland\|Italy\|Korea, Republic of\|Lithuania\|Malaysia\|Poland\|Romania\|Russian Federation\|Slovakia\|Thailand\|Ukraine	1
United States\|Belgium\|Brazil\|Bulgaria\|Canada\|Czechia\|France\|Hungary\|Italy\|Mexico\|Peru\|Spain	1
United States\|Belgium\|Canada\|China\|France\|Germany\|Hong Kong\|Italy\|Korea, Republic of\|Netherlands\|Singapore\|Spain\|Taiwan\|Thailand\|United Kingdom	1
United States\|Belgium\|Canada\|Czechia\|France\|Germany\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Singapore\|Spain	1
United States\|Belgium\|Canada\|France\|Germany\|Hong Kong\|Ireland\|Israel\|Italy\|Japan\|Korea, Republic of\|Lebanon\|Netherlands\|Portugal\|Russian Federation\|Singapore\|Spain\|Switzerland\|Turkey\|United Kingdom	1
United States\|Belgium\|Canada\|France\|Germany\|Israel\|Italy\|Spain	1
United States\|Belgium\|Canada\|France\|Germany\|Italy\|Korea, Republic of\|Poland\|Spain\|Sweden\|Thailand\|Turkey\|United Kingdom	1
United States\|Belgium\|Canada\|France\|Israel\|Italy\|Netherlands\|Spain	1
United States\|Belgium\|Canada\|France\|Italy\|Poland\|Spain\|United Kingdom	1
United States\|Belgium\|Canada\|Germany\|Poland\|United Kingdom	1
United States\|Belgium\|Canada\|Spain	1
United States\|Belgium\|China\|France\|Germany\|Hong Kong\|Italy\|Korea, Republic of\|Netherlands\|Singapore\|Spain\|Taiwan\|United Kingdom	1
United States\|Belgium\|China\|France\|Germany\|Hong Kong\|Japan\|Korea, Republic of\|Malaysia\|Netherlands\|Russian Federation\|Singapore\|Spain\|Taiwan\|Thailand\|Vietnam	1
United States\|Belgium\|Denmark\|France\|Hungary	1
United States\|Belgium\|France	1
United States\|Belgium\|France\|Germany\|Greece\|Israel\|Netherlands\|Spain	1
United States\|Belgium\|France\|Germany\|Israel\|Italy\|Korea, Republic of\|Netherlands\|Spain\|United Kingdom	1
United States\|Belgium\|France\|Germany\|Italy\|Netherlands\|Romania\|Spain	1
United States\|Belgium\|France\|Germany\|Korea, Republic of\|Poland\|Spain\|Taiwan\|United Kingdom	1
United States\|Belgium\|France\|Italy\|Spain\|Taiwan\|Turkey	1
United States\|Belgium\|France\|Korea, Republic of\|Spain	1
United States\|Belgium\|France\|Netherlands\|United Kingdom	1
United States\|Belgium\|Germany\|Israel\|Italy\|Netherlands\|Poland\|Spain\|United Kingdom	1
United States\|Belgium\|Germany\|Italy\|Poland\|United Kingdom	1
United States\|Belgium\|Korea, Republic of\|Netherlands\|Taiwan\|United Kingdom	1
United States\|Belgium\|United Kingdom	1
United States\|Brazil	1
United States\|Brazil\|Bulgaria\|Canada\|China\|Czech Republic\|France\|Hungary\|Italy\|Korea, Republic of\|Latvia\|Lithuania\|Netherlands\|Poland\|Romania\|Slovakia\|South Africa\|Taiwan\|Thailand\|Ukraine	1
United States\|Brazil\|Bulgaria\|China\|Germany\|Hong Kong\|Hungary\|Japan\|Korea, Republic of\|Mexico\|Peru\|Poland\|Russian Federation\|South Africa\|Taiwan\|Thailand\|Ukraine\|United Kingdom\|Vietnam	1
United States\|Brazil\|Bulgaria\|France\|Germany\|Hungary\|Netherlands\|Poland	1
United States\|Brazil\|China\|France\|Germany\|Greece\|Hungary\|Italy\|Japan\|Korea, Republic of\|Poland\|Romania\|Russian Federation\|Serbia\|Spain\|Thailand\|Turkey\|Ukraine\|United Kingdom	1
United States\|Bulgaria\|Hungary\|Russian Federation\|Serbia	1
United States\|Bulgaria\|Romania	1
United States\|Canada\|Chile	1
United States\|Canada\|China\|France\|Hong Kong\|Japan\|Korea, Republic of\|Singapore\|Spain\|Taiwan	1
United States\|Canada\|Czech Republic\|Korea, Republic of\|United Kingdom	1
United States\|Canada\|Denmark\|France\|Russian Federation	1
United States\|Canada\|France	1
United States\|Canada\|France\|Germany\|Greece\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Romania\|Spain\|Taiwan\|Turkey\|United Kingdom	1
United States\|Canada\|France\|Germany\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Singapore\|Spain\|United Kingdom	1
United States\|Canada\|France\|Germany\|Hungary\|Japan\|Poland	1
United States\|Canada\|France\|Germany\|Hungary\|Spain	1
United States\|Canada\|France\|Germany\|Korea, Republic of\|Netherlands\|Norway\|Singapore\|Spain\|Turkey	1
United States\|Canada\|France\|Hong Kong\|Italy\|Poland\|Portugal\|Spain\|Taiwan	1
United States\|Canada\|France\|Italy\|Portugal\|Spain\|Switzerland	1
United States\|Canada\|France\|Korea, Republic of\|Spain	1
United States\|Canada\|France\|Mexico\|Netherlands\|Spain\|Taiwan	1
United States\|Canada\|France\|Singapore\|Taiwan	1
United States\|Canada\|Germany	1
United States\|Canada\|Germany\|Israel\|Italy\|Spain	1
United States\|Canada\|Germany\|Israel\|Netherlands\|Spain	1
United States\|Canada\|Germany\|Japan\|Korea, Republic of\|Netherlands\|Singapore\|Spain\|Taiwan	1
United States\|Canada\|Hong Kong	1
United States\|Canada\|Hong Kong\|Italy\|Japan\|Korea, Republic of\|Spain\|Taiwan	1
United States\|Canada\|Hong Kong\|Korea, Republic of\|Singapore\|Thailand	1
United States\|Canada\|Hungary\|India\|Netherlands\|Poland\|Serbia\|United Kingdom	1
United States\|Canada\|Hungary\|Israel\|Spain	1
United States\|Canada\|Hungary\|Italy\|Netherlands\|Poland\|Romania\|Spain	1
United States\|Canada\|Hungary\|Poland\|Russian Federation\|Slovakia	1
United States\|Canada\|Ireland\|Peru\|South Africa	1
United States\|Canada\|Israel	1
United States\|Canada\|Israel\|Italy\|Poland\|Romania\|Russian Federation\|Serbia\|Spain\|Switzerland\|Ukraine\|United Kingdom	1
United States\|Canada\|Italy\|Spain	1
United States\|Canada\|Japan\|Korea, Republic of\|Poland\|Russian Federation\|Taiwan\|Ukraine	1
United States\|Canada\|Poland	1
United States\|Canada\|Poland\|Portugal\|Spain\|United Kingdom	1
United States\|Canada\|Saudi Arabia	1
United States\|Canada\|Switzerland	1
United States\|Chile\|Argentina\|Australia\|Brazil\|Germany\|Italy\|United Kingdom	1
United States\|China\|Argentina\|Australia\|Canada\|Chile\|France\|Germany\|Israel\|Japan\|Korea, Republic of\|New Zealand\|Poland\|Russian Federation\|Spain\|Turkey\|United Kingdom	1
United States\|China\|Germany\|Italy\|Japan\|Korea, Republic of\|Spain\|Taiwan\|United Kingdom	1
United States\|Czech Republic\|France\|Poland\|Spain\|United Kingdom	1
United States\|Czech Republic\|Greece\|Hungary\|Netherlands\|Slovakia	1
United States\|Czech Republic\|Hungary	1
United States\|Czechia\|France\|Germany\|Hungary\|Israel\|Italy\|Poland\|Spain\|United Kingdom	1
United States\|Denmark\|Japan\|Korea, Republic of\|Netherlands\|Norway\|Spain\|Sweden	1
United States\|Denmark\|Russian Federation	1
United States\|Estonia\|France\|Germany\|Japan\|Korea, Republic of\|Poland\|Russian Federation\|United Kingdom	1
United States\|Finland\|France\|Germany\|India\|Italy\|South Africa\|Spain\|Thailand	1
United States\|France\|Germany\|Greece\|Hungary\|Japan\|Netherlands\|Russian Federation\|Spain\|Taiwan\|Turkey	1
United States\|France\|Germany\|Greece\|Italy\|Spain	1
United States\|France\|Germany\|Italy	1
United States\|France\|Germany\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Norway\|Spain\|Taiwan\|United Kingdom	1
United States\|France\|Germany\|Italy\|Korea, Republic of\|Portugal	1
United States\|France\|Germany\|Italy\|Spain\|United Kingdom	1
United States\|France\|Germany\|Japan\|Korea, Republic of\|Malaysia\|Spain\|Taiwan	1
United States\|France\|Germany\|Japan\|Spain\|United Kingdom	1
United States\|France\|Germany\|Spain	1
United States\|France\|Greece\|Hungary\|Italy\|Korea, Republic of\|Netherlands\|Spain	1
United States\|France\|Hong Kong\|Korea, Republic of\|Spain\|United Kingdom	1
United States\|France\|Israel\|Japan\|United Kingdom	1
United States\|France\|Israel\|Luxembourg\|Spain	1
United States\|France\|Israel\|Spain\|Taiwan	1
United States\|France\|Italy\|Korea, Republic of\|Spain\|Taiwan	1
United States\|France\|Italy\|Spain	1
United States\|France\|Italy\|Taiwan\|United Kingdom	1
United States\|France\|Japan\|Netherlands\|Spain	1
United States\|France\|Japan\|Spain	1
United States\|France\|Korea, Republic of\|Serbia\|Spain\|Taiwan	1
United States\|France\|Korea, Republic of\|Spain\|Taiwan	1
United States\|France\|Korea, Republic of\|Spain\|Turkey	1
United States\|France\|Netherlands	1
United States\|France\|Netherlands\|Spain	1
United States\|France\|Spain	1
United States\|Germany\|Argentina\|Austria\|Belgium\|Brazil\|Canada\|Chile\|Colombia\|Czech Republic\|Denmark\|Greece\|Hong Kong\|Hungary\|Italy\|Korea, Republic of\|Netherlands\|Norway\|Poland\|Russian Federation\|Slovakia\|Spain\|Switzerland\|Taiwan\|Thailand\|United Kingdom	1
United States\|Germany\|Australia\|Belgium\|Canada\|China\|France\|Hong Kong\|Hungary\|Israel\|Italy\|Japan\|Korea, Republic of\|Netherlands\|Poland\|Portugal\|Romania\|Russian Federation\|Spain\|Taiwan\|Ukraine\|United Kingdom	1
United States\|Germany\|Hong Kong\|Japan	1
United States\|Germany\|Hungary\|Romania	1
United States\|Germany\|India\|Korea, Republic of	1
United States\|Germany\|Italy\|Korea, Republic of\|Poland\|Spain\|Switzerland	1
United States\|Germany\|Italy\|Spain\|United Kingdom	1
United States\|Germany\|Japan\|Korea, Republic of\|Puerto Rico	1
United States\|Germany\|Korea, Republic of\|Mexico\|Poland\|Russian Federation	1
United States\|Germany\|Korea, Republic of\|Netherlands\|Spain\|Taiwan\|United Kingdom	1
United States\|Germany\|Latvia\|Poland\|Russian Federation\|Ukraine	1
United States\|Germany\|Puerto Rico	1
United States\|Hong Kong\|Korea, Republic of\|Malaysia\|Singapore\|Taiwan\|Thailand	1
United States\|Hong Kong\|Korea, Republic of\|Singapore\|Taiwan	1
United States\|Hong Kong\|Netherlands\|Singapore\|Taiwan	1
United States\|Hungary\|Italy\|Korea, Republic of\|Poland\|Russian Federation\|Spain\|Taiwan	1
United States\|Hungary\|Korea, Republic of\|Romania\|Russian Federation\|Taiwan	1
United States\|Hungary\|Poland\|Russian Federation	1
United States\|India\|Poland\|Romania	1
United States\|India\|United Kingdom	1
United States\|Israel\|Japan\|Spain	1
United States\|Israel\|Spain	1
United States\|Italy\|Argentina\|Australia\|Austria\|Belgium\|Brazil\|Canada\|China\|Czech Republic\|Denmark\|France\|Germany\|Greece\|Hong Kong\|Hungary\|India\|Ireland\|Israel\|Korea, Republic of\|Mexico\|Netherlands\|Poland\|Portugal\|Romania\|Russian Federation\|Singapore\|Slovakia\|Spain\|Sweden\|Switzerland\|Taiwan\|United Kingdom	1
United States\|Italy\|Japan\|Poland\|Romania\|Russian Federation\|Spain\|Switzerland\|Taiwan\|Ukraine\|United Kingdom	1
United States\|Italy\|Korea, Republic of\|Malaysia\|Spain	1
United States\|Italy\|Korea, Republic of\|Spain	1
United States\|Italy\|Korea, Republic of\|Taiwan	1
United States\|Italy\|Lithuania	1
United States\|Italy\|Spain	1
United States\|Japan\|Korea, Republic of	1
United States\|Japan\|Korea, Republic of\|Spain\|Taiwan	1
United States\|Japan\|Netherlands\|Spain\|Taiwan	1
United States\|Korea, Republic of\|Netherlands\|Spain\|Taiwan\|United Kingdom	1
United States\|Korea, Republic of\|Spain\|Taiwan	1
United States\|Korea, Republic of\|Taiwan	1
United States\|Norway\|United Kingdom	1
United States\|Puerto Rico\|South Africa	1
United States\|Russian Federation\|Ukraine	1
United States\|South Africa	1
United States\|Switzerland	1

Sites per Study

Site_count	Study_Count
1	918
2	165
3	88
4	80
5	75
6	33
7	56
8	39
9	35
10	38
11	29
12	33
13	30
14	18
15	24
16	28
17	15
18	12
19	19
20	21
21	18
22	12
23	11
24	14
25	13
26	10
27	7
28	9
29	7
30	14
31	9
32	9
33	11
34	4
35	8
36	6
37	8
38	10
39	4
40	5
41	3
42	10
43	4
44	11
45	3
46	4
47	8
48	3
49	1
50	5
51	4
52	7
53	2
54	2
55	2
56	4
57	3
58	2
59	5
60	6
61	1
62	2
63	1
64	3
65	4
66	2
67	2
68	2
69	7
70	3
71	4
72	4
73	3
74	4
75	2
76	2
77	1
78	3
79	3
80	2
81	1
82	1
84	5
85	3
86	3
87	2
88	2
89	1
90	3
91	3
92	3
93	4
94	3
96	1
97	1
98	1
99	1
101	4
103	1
105	3
108	1
109	1
110	3
111	1
112	1
113	2
114	2
115	2
116	1
117	3
118	2
119	1
120	2
121	1
122	1
123	4
124	2
125	1
126	1
127	1
129	1
132	1
133	5
134	1
135	2
136	1
137	1
139	1
140	1
141	4
143	2
144	1
145	1
147	2
148	1
150	1
152	1
153	1
154	3
155	3
156	1
157	2
158	1
160	1
161	1
162	2
163	1
166	1
167	2
168	1
170	1
175	1
179	1
181	1
182	3
183	1
185	1
186	1
187	1
188	2
189	2
192	1
196	1
197	1
199	1
200	1
204	1
207	1
208	1
210	2
212	1
213	2
216	1
224	2
227	1
228	1
230	1
231	2
233	1
237	1
240	2
242	1
247	2
248	1
249	1
257	1
260	1
263	1
264	2
271	1
279	1
287	1
295	2
301	1
305	1
332	1
339	1
348	1
369	2
386	1
418	1
457	1
468	1
484	1
532	1
544	1
605	1
638	1
658	1
743	1
873	1
892	1
931	1
1175	1
1498	2

Phase

Phase	Study_Count
Phase 2	1017
Phase 1	423
Phase 3	359
Phase 1/Phase 2	228
N/A	180
Phase 4	43
Phase 2/Phase 3	28
Early Phase 1	16

Number of Arms

Number_of_Arms	Count_of_Studies
1	945
2	798
3	151
4	81
5	22
6	18
7	11
8	5
9	8
10	5
11	2
12	1
13	1
14	2
15	1
16	1
18	2
19	1
24	1
NA	238

Enrollment Metrics by Phase

Measure	Early.Phase.1	N.A	Phase.1	Phase.1.Phase.2	Phase.2	Phase.2.Phase.3	Phase.3	Phase.4
Min.	3.0	3.0000	1.00000	2.0000	1.00000	40.0000	1.000	5.0000
1st Qu.	12.0	29.0000	18.00000	40.0000	40.00000	116.0000	275.750	53.0000
Median	22.5	58.0000	31.00000	70.0000	65.00000	187.0000	453.500	107.5000
Mean	32.5	443.8371	60.51074	103.5946	97.38641	634.7857	550.321	384.6905
3rd Qu.	32.0	150.7500	56.50000	122.5000	120.00000	409.7500	671.500	195.0000
Max.	180.0	39981.0000	1260.00000	970.0000	1805.00000	10000.0000	5000.000	6586.0000

Trial Group Type

group_type	Group_Count
Experimental	3086
Active Comparator	560
NA	238
Placebo Comparator	167
Other	99
No Intervention	45
Sham Comparator	3

Intervention Model

intervention_model	Study_Count
Single Group Assignment	1113
Parallel Assignment	997
NA	93
Sequential Assignment	58
Crossover Assignment	27
Factorial Assignment	6

Primary Purpose

primary_purpose	Study_Count
Treatment	2123
Diagnostic	61
Supportive Care	34
Other	30
Prevention	14
Basic Science	11
NA	8
Health Services Research	6
Screening	6
Device Feasibility	1

Observational Studies

Studies by Country

Country	Study_Count
China	58
United States	54
France	29
NA	19
Germany	12
Netherlands	11
Spain	10
Korea, Republic of	9
Japan	8
Taiwan	8
Canada	7
Belgium	5
Denmark	5
Italy	5
United Kingdom	5
Greece	4
United States\|Canada	4
Austria	3
Mexico	3
Poland	3
Singapore	3
Brazil	2
Egypt	2
Ireland	2
Russian Federation	2
Argentina	1
Argentina\|Chile\|Colombia\|Dominican Republic\|India\|Mexico\|Peru\|Taiwan\|Thailand\|Uruguay	1
Argentina\|Chile\|Colombia\|Uruguay	1
Australia	1
Australia\|Belgium\|France\|Germany\|Israel\|Italy\|Netherlands\|Norway\|Switzerland\|United Kingdom	1
Australia\|New Zealand\|Singapore	1
Austria\|Belgium\|Denmark\|Germany\|Greece\|Hungary\|Italy\|Lithuania\|Luxembourg\|Netherlands\|Spain\|Sweden\|United Kingdom	1
Austria\|Belgium\|Germany\|Spain\|Switzerland	1
Austria\|Germany	1
Bahrain\|Qatar\|United Arab Emirates	1
Belgium\|France\|Germany\|Greece\|Italy\|Portugal\|Spain\|Turkey	1
China\|Japan\|Korea, Republic of	1
Czechia\|Germany\|Poland\|Spain\|Switzerland\|United Kingdom	1
Egypt\|Lebanon\|Morocco\|Saudi Arabia\|United Arab Emirates	1
Finland	1
Hong Kong\|Korea, Republic of\|Malaysia\|Singapore	1
Hungary	1
India	1
Jordan	1
Kazakhstan	1
Korea, Republic of\|Singapore	1
Norway	1
Serbia	1
Sweden	1
United States\|Austria\|Canada\|France\|Germany\|Italy\|Japan\|Korea, Republic of\|Mexico\|Poland\|Singapore\|Spain\|Taiwan	1
United States\|Bolivia\|Mexico\|Peru\|Venezuela	1
United States\|Denmark	1

Sites per Study

Site_count	Study_Count
1	176
2	8
3	8
4	7
5	9
6	5
7	3
8	3
9	5
10	9
11	5
12	2
13	1
14	4
15	2
17	2
18	1
21	1
22	2
23	4
24	2
25	1
26	2
28	1
29	2
31	2
32	2
33	2
35	1
37	1
39	1
41	1
42	1
43	1
44	1
46	1
50	1
56	1
61	1
63	1
71	1
72	1
73	1
81	1
88	1
92	1
101	1
111	1
118	1
120	1
133	1
152	1
170	1
198	1
299	1
405	1
432	1

Enrollment Metrics

Measure	Observational
Min	1.0000
1st Qu	70.0000
Median	165.0000
Mean	782.3345
3rd Qu	503.2500
Max	50000.0000

Observation Model

observational_model	Study_Count
Cohort	188
Case-Only	66
Other	17
NA	10
Case-Control	9
Case Control	6
Case-Crossover	2
Defined Population	1
Ecologic or Community	1

Time Perspective

time_perspective	Study_Count
Prospective	188
Retrospective	87
Cross-Sectional	14
Other	7
NA	3
Longitudinal, Prospective	1

Registries

Studies by Country

Country	Study_Count
China	7
Korea, Republic of	3
Belgium	2
Germany	2
Greece	2
Japan	2
NA	2
Denmark\|Norway	1
Egypt	1
France	1
Netherlands	1
United Kingdom	1
United States	1

Sites per Study

Site_count	Study_Count
1	19
2	1
5	1
8	1
34	1
44	2
73	1

Enrollment Metrics

Measure	Registries
Min	20.000
1st Qu	132.000
Median	315.000
Mean	1034.808
3rd Qu	989.000
Max	7500.000

Registry Model

observational_model	Study_Count
Cohort	20
Other	4
Case-Only	2

Time Perspective

time_perspective	Study_Count
Prospective	21
Other	5

Follow-up

target_duration	Study_Count
3 Years	11
5 Years	4
1 Year	2
24 Months	2
1 Day	1
12 Months	1
2 Years	1
20 Months	1
36 Months	1
4 Months	1
7 Years	1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT04455984	Multimodality Treatment Including Curative Resection of Advanced NSCLC	https://ClinicalTrials.gov/show/NCT04455984	Recruiting	Medical University of Vienna	2020-08-01
NCT04165798	Umbrella Master Protocol: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYNOTE-U01)	https://ClinicalTrials.gov/show/NCT04165798	Recruiting	Merck Sharp & Dohme Corp.	2032-02-13
NCT03389399	Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases	https://ClinicalTrials.gov/show/NCT03389399	Recruiting	University of Colorado, Denver	2021-08-30
NCT03375242	Safety and Efficacy of Xalkori ROS1	https://ClinicalTrials.gov/show/NCT03375242	Recruiting	Pfizer	2022-03-14
NCT03373955	A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients	https://ClinicalTrials.gov/show/NCT03373955	Recruiting	Sichuan University	2020-07-31
NCT03370770	Afatinib Osimertinib Sequencing NIS	https://ClinicalTrials.gov/show/NCT03370770	Completed	Boehringer Ingelheim	2019-11-28
NCT03816657	The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT03816657	Active, not recruiting	Fondazione Ricerca Traslazionale	2017-05-15
NCT03363685	Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis	https://ClinicalTrials.gov/show/NCT03363685	Recruiting	Ruijin Hospital	2022-11-01
NCT03289780	Clinical Effectiveness Assessment of VeriStratÂ® Testing and Validation of Immunotherapy Tests in NSCLC Subjects	https://ClinicalTrials.gov/show/NCT03289780	Recruiting	Biodesix, Inc.	2019-06-30
NCT03273790	A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan	https://ClinicalTrials.gov/show/NCT03273790	Active, not recruiting	Bristol-Myers Squibb	2019-10-31
NCT03271554	Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea	https://ClinicalTrials.gov/show/NCT03271554	Recruiting	Hoffmann-La Roche	2021-12-31
NCT03258788	A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03258788	Recruiting	The Christie NHS Foundation Trust	2019-12-31
NCT03236675	Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients	https://ClinicalTrials.gov/show/NCT03236675	Active, not recruiting	Exosome Diagnostics, Inc.	2020-02-29
NCT03219970	Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.	https://ClinicalTrials.gov/show/NCT03219970	Active, not recruiting	AstraZeneca	2020-05-31
NCT03216551	Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC	https://ClinicalTrials.gov/show/NCT03216551	Recruiting	Fudan University	2021-04-01
NCT03199599	Prognostic PET/CT Model in Non Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03199599	Completed	Poitiers University Hospital	2019-08-31
NCT03170284	Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03170284	Completed	Hoffmann-La Roche	2012-08-01
NCT03137264	Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients	https://ClinicalTrials.gov/show/NCT03137264	Completed	AstraZeneca	2018-11-10
NCT03141957	Hypermetabolism in the Elderly Lung Cancer Patient	https://ClinicalTrials.gov/show/NCT03141957	Completed	University of Paris 5 - Rene Descartes	2016-11-30
NCT03132493	Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient	https://ClinicalTrials.gov/show/NCT03132493	Completed	Spanish Lung Cancer Group	2017-12-01
NCT03133234	Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC	https://ClinicalTrials.gov/show/NCT03133234	Completed	AstraZeneca	2017-09-13
NCT03130192	A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy	https://ClinicalTrials.gov/show/NCT03130192	Recruiting	Chung Shan Medical University	2021-06-07
NCT03092739	A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens	https://ClinicalTrials.gov/show/NCT03092739	Completed	Hoffmann-La Roche	2018-01-08
NCT03059641	Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China	https://ClinicalTrials.gov/show/NCT03059641	Completed	Geneplus-Beijing Co. Ltd.	2019-12-31
NCT03055715	Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC	https://ClinicalTrials.gov/show/NCT03055715	Completed	Martin-Luther-UniversitÃ¤t Halle-Wittenberg	2018-04-01
NCT03042221	Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy	https://ClinicalTrials.gov/show/NCT03042221	Recruiting	University of Colorado, Denver	2020-09-30
NCT03037086	Asia PDL1 Study Among NSCLC Patients	https://ClinicalTrials.gov/show/NCT03037086	Completed	AstraZeneca	2017-02-27
NCT02980536	cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China	https://ClinicalTrials.gov/show/NCT02980536	Active, not recruiting	Berry Genomics Co., Ltd.	2018-10-31
NCT02972216	Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy	https://ClinicalTrials.gov/show/NCT02972216	Completed	Yung Shin Pharm. Ind. Co., Ltd.	2016-10-31
NCT02968979	Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.	https://ClinicalTrials.gov/show/NCT02968979	Completed	Chugai Pharma France	2016-10-31
NCT02966769	N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation	https://ClinicalTrials.gov/show/NCT02966769	Completed	Grupo de InvestigaciÃ³n ClÃnica en OncologÃa Radioterapia	2017-03-31
NCT03232593	A Study of Atezolizumab (TecentriqÂ®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)	https://ClinicalTrials.gov/show/NCT03232593	Recruiting	Hoffmann-La Roche	2023-01-11
NCT02932345	Gefitinib Long-term Survivor Study	https://ClinicalTrials.gov/show/NCT02932345	Completed	AstraZeneca	2017-07-04
NCT02933346	Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program	https://ClinicalTrials.gov/show/NCT02933346	Active, not recruiting	Intergroupe Francophone de Cancerologie Thoracique	2018-01-31
NCT02910999	Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy	https://ClinicalTrials.gov/show/NCT02910999	Active, not recruiting	Bristol-Myers Squibb	2023-12-31
NCT02906852	Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing	https://ClinicalTrials.gov/show/NCT02906852	Completed	Inivata	2018-05-31
NCT02848872	Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02848872	Completed	Duke University	2019-04-02
NCT02827344	PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02827344	Recruiting	University Hospital, Toulouse	2019-10-31
NCT02799862	Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC	https://ClinicalTrials.gov/show/NCT02799862	Active, not recruiting	iOMEDICO AG	2019-12-07
NCT02777567	KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)	https://ClinicalTrials.gov/show/NCT02777567	Completed	AstraZeneca	2020-03-19
NCT02764606	CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02764606	Recruiting	Hospices Civils de Lyon	2025-12-31
NCT02740894	Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?	https://ClinicalTrials.gov/show/NCT02740894	Completed	Taipei Veterans General Hospital, Taiwan	2016-04-30
NCT02727335	Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements	https://ClinicalTrials.gov/show/NCT02727335	Completed	Intergroupe Francophone de Cancerologie Thoracique	2015-12-31
NCT02718651	Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer	https://ClinicalTrials.gov/show/NCT02718651	Completed	University of Aarhus	2018-12-31
NCT02714335	The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients	https://ClinicalTrials.gov/show/NCT02714335	Completed	National Taiwan University	2013-11-30
NCT02695849	A Study of Prevalence of EGFR Mutations in Participants With NSCLC	https://ClinicalTrials.gov/show/NCT02695849	Completed	Hoffmann-La Roche	2015-05-31
NCT02679170	Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management (IDEALK)	https://ClinicalTrials.gov/show/NCT02679170	Recruiting	Pfizer	2020-06-30
NCT02671422	LUME BioNIS: a Biomarker Study in Patients With NSCLC	https://ClinicalTrials.gov/show/NCT02671422	Completed	Boehringer Ingelheim	2019-09-03
NCT02658747	Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK	https://ClinicalTrials.gov/show/NCT02658747	Completed	Hoffmann-La Roche	2016-07-25
NCT02645318	Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02645318	Completed	Peking University People’s Hospital	2015-07-31
NCT02623257	EGFR Mutations on ctDNA in Patients With Advanced NSCLC	https://ClinicalTrials.gov/show/NCT02623257	Completed	First People’s Hospital of Hangzhou	2017-07-31
NCT02619929	Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria	https://ClinicalTrials.gov/show/NCT02619929	Completed	Pierre Fabre Pharma GmbH	2018-03-31
NCT02620657	Evaluate EGFR Mutation Status and Impact Factors in North China	https://ClinicalTrials.gov/show/NCT02620657	Completed	Guangdong Association of Clinical Trials	2017-11-08
NCT02595450	A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02595450	Completed	Hoffmann-La Roche	2014-11-30
NCT02575560	Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT02575560	Completed	Qingdao Central Hospital	2017-09-30
NCT02038413	State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients	https://ClinicalTrials.gov/show/NCT02038413	Completed	Maastricht Radiation Oncology	2014-10-31
NCT02146170	Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors	https://ClinicalTrials.gov/show/NCT02146170	Recruiting	National Institutes of Health Clinical Center (CC)	2024-04-30
NCT02321046	An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).	https://ClinicalTrials.gov/show/NCT02321046	Completed	AstraZeneca	2019-06-28
NCT02511288	LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02511288	Recruiting	Centre Leon Berard	2026-03-31
NCT02475720	Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)	https://ClinicalTrials.gov/show/NCT02475720	Completed	AstraZeneca	2016-03-16
NCT02458651	Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China	https://ClinicalTrials.gov/show/NCT02458651	Completed	Hoffmann-La Roche	2018-10-30
NCT02445924	Micro RNA Genetic Signature in NSCLC Egyptian Patients	https://ClinicalTrials.gov/show/NCT02445924	Completed	Tanta University	2016-01-31
NCT02428049	Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma	https://ClinicalTrials.gov/show/NCT02428049	Recruiting	Sykehuset i Vestfold HF	2018-12-31
NCT02418234	T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure	https://ClinicalTrials.gov/show/NCT02418234	Completed	First People’s Hospital of Hangzhou	2016-04-30
NCT02410603	Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer	https://ClinicalTrials.gov/show/NCT02410603	Recruiting	Mayo Clinic	2020-06-30
NCT02392455	VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT02392455	Recruiting	Boehringer Ingelheim	2022-12-31
NCT02380196	The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02380196	Completed	Abramson Cancer Center of the University of Pennsylvania	2019-12-31
NCT02370303	A Study to Isolate and Test Circulating Tumor Cells Using the ClearCellÂ® FX EP+ System	https://ClinicalTrials.gov/show/NCT02370303	Completed	Mayo Clinic	2016-07-09
NCT02338583	Powered Surgical Stapler in VATS Lung Resection Procedures in China	https://ClinicalTrials.gov/show/NCT02338583	Completed	Ethicon Endo-Surgery	2015-04-01
NCT02304406	Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa	https://ClinicalTrials.gov/show/NCT02304406	Completed	Pfizer	2018-02-11
NCT02293733	Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)	https://ClinicalTrials.gov/show/NCT02293733	Completed	Groupe Francais De Pneumo-Cancerologie	2014-03-31
NCT02285361	GIOTRIF rPMS in Korean Patients With NSCLC	https://ClinicalTrials.gov/show/NCT02285361	Completed	Boehringer Ingelheim	2019-12-31
NCT02271581	Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer	https://ClinicalTrials.gov/show/NCT02271581	Recruiting	Leo W. Jenkins Cancer Center	2020-07-31
NCT02245100	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02245100	Recruiting	Thomas Jefferson University	2020-07-31
NCT02196675	Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea	https://ClinicalTrials.gov/show/NCT02196675	Completed	Ethicon Endo-Surgery	2015-01-31
NCT02169349	Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT02169349	Completed	Rennes University Hospital	2016-06-30
NCT02171286	The Oncopanel Pilot (TOP) Study	https://ClinicalTrials.gov/show/NCT02171286	Completed	British Columbia Cancer Agency	2017-03-31
NCT02133508	A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)	https://ClinicalTrials.gov/show/NCT02133508	Completed	Hoffmann-La Roche	2016-06-10
NCT02131259	Long-term Observation PMS for Afatinib	https://ClinicalTrials.gov/show/NCT02131259	Completed	Boehringer Ingelheim	2016-12-28
NCT02109549	Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.	https://ClinicalTrials.gov/show/NCT02109549	Completed	Maastricht Radiation Oncology	2015-12-31
NCT01300429	Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus	https://ClinicalTrials.gov/show/NCT01300429	Active, not recruiting	Memorial Sloan Kettering Cancer Center	2021-02-28
NCT01290809	Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients	https://ClinicalTrials.gov/show/NCT01290809	Completed	Maastricht Radiation Oncology	2015-03-31
NCT01294280	Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy	https://ClinicalTrials.gov/show/NCT01294280	Recruiting	Alliance for Clinical Trials in Oncology	2100-01-31
NCT01279408	Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)	https://ClinicalTrials.gov/show/NCT01279408	Active, not recruiting	University Health Network, Toronto	2028-11-30
NCT02047903	GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations	https://ClinicalTrials.gov/show/NCT02047903	Completed	Boehringer Ingelheim	2018-12-31
NCT02042105	A Prospective Epidemiologic Study of ALK-Positive NSCLC in China	https://ClinicalTrials.gov/show/NCT02042105	Completed	Guangdong Association of Clinical Trials	2015-04-15
NCT01991418	Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)	https://ClinicalTrials.gov/show/NCT01991418	Completed	Hunan Province Tumor Hospital	2016-02-29
NCT01994057	A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in NSCLC Patients Treatment	https://ClinicalTrials.gov/show/NCT01994057	Recruiting	Sun Yat-sen University	2021-10-31
NCT01985113	Correlation Research of Thioredoxin Reductase in Lung Cancer	https://ClinicalTrials.gov/show/NCT01985113	Completed	Hunan Province Tumor Hospital	2016-02-29
NCT01980212	Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01980212	Completed	Hunan Province Tumor Hospital	2016-12-01
NCT01956331	Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer	https://ClinicalTrials.gov/show/NCT01956331	Completed	Groupe Francais De Pneumo-Cancerologie	2013-06-30
NCT01947868	Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor	https://ClinicalTrials.gov/show/NCT01947868	Completed	AstraZeneca	2015-09-30
NCT01941303	Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease	https://ClinicalTrials.gov/show/NCT01941303	Completed	Maastricht Radiation Oncology	2015-09-30
NCT01934465	Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment	https://ClinicalTrials.gov/show/NCT01934465	Completed	Hellenic Oncology Research Group	2013-12-31
NCT01893268	An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice	https://ClinicalTrials.gov/show/NCT01893268	Completed	Hoffmann-La Roche	2018-03-20
NCT04351334	Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns	https://ClinicalTrials.gov/show/NCT04351334	Active, not recruiting	Pfizer	2020-07-31
NCT01888601	TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)	https://ClinicalTrials.gov/show/NCT01888601	Recruiting	University College, London	2023-11-30
NCT01843192	Powered Echelon Device in VATS Surgery	https://ClinicalTrials.gov/show/NCT01843192	Completed	Ethicon Endo-Surgery	2014-05-31
NCT01837511	Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients	https://ClinicalTrials.gov/show/NCT01837511	Completed	GlaxoSmithKline	2008-01-31
NCT01837186	Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT01837186	Completed	University Hospital, Gasthuisberg	2012-09-30
NCT01836133	An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)	https://ClinicalTrials.gov/show/NCT01836133	Completed	Hoffmann-La Roche	2016-01-31
NCT01830426	Circulating Tumor Cells in Non-Small Cell Lung Carcinoma	https://ClinicalTrials.gov/show/NCT01830426	Completed	Epic Sciences	2015-12-31
NCT01790217	An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)	https://ClinicalTrials.gov/show/NCT01790217	Completed	Hoffmann-La Roche	2013-08-31
NCT01795352	Retrospective Study in a NSCLC M+ p	https://ClinicalTrials.gov/show/NCT01795352	Completed	AstraZeneca	2013-10-31
NCT01772225	NSCLC Burden of Illness Study	https://ClinicalTrials.gov/show/NCT01772225	Completed	GlaxoSmithKline	2014-01-31
NCT01740804	Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC	https://ClinicalTrials.gov/show/NCT01740804	Completed	Guangdong Association of Clinical Trials	2016-04-30
NCT01726309	Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4	https://ClinicalTrials.gov/show/NCT01726309	Active, not recruiting	Cancer Trials Ireland	2024-08-31
NCT01723878	ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations	https://ClinicalTrials.gov/show/NCT01723878	Completed	Hoffmann-La Roche	2017-06-20
NCT01721252	Tarceva. ICORG 08-41	https://ClinicalTrials.gov/show/NCT01721252	Completed	Cancer Trials Ireland	2013-08-31
NCT01700582	French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings	https://ClinicalTrials.gov/show/NCT01700582	Completed	Intergroupe Francophone de Cancerologie Thoracique	2013-04-30
NCT01662635	Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)	https://ClinicalTrials.gov/show/NCT01662635	Completed	Instituto Nacional de Cancerologia de Mexico	2014-09-30
NCT01664533	An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy	https://ClinicalTrials.gov/show/NCT01664533	Completed	Hoffmann-La Roche	2013-08-31
NCT01659970	PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01659970	Completed	Hoffmann-La Roche	2014-04-30
NCT01660776	BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology	https://ClinicalTrials.gov/show/NCT01660776	Completed	Rennes University Hospital	2017-10-02
NCT01630122	Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates	https://ClinicalTrials.gov/show/NCT01630122	Completed	Wake Forest University Health Sciences	2015-08-18
NCT01620853	Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)	https://ClinicalTrials.gov/show/NCT01620853	Completed	Applied Spectral Imaging Ltd.	2013-01-31
NCT01598597	An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)	https://ClinicalTrials.gov/show/NCT01598597	Completed	Genentech, Inc.	2014-11-30
NCT01597258	Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)	https://ClinicalTrials.gov/show/NCT01597258	Completed	Pfizer	2018-03-16
NCT04018183	The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04018183	Completed	National Taiwan University Hospital	2020-03-24
NCT01562665	Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf	https://ClinicalTrials.gov/show/NCT01562665	Completed	AstraZeneca	2015-02-28
NCT01551251	Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01551251	Completed	Chang Gung Memorial Hospital	2010-12-31
NCT01540045	Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01540045	Completed	Instituto Nacional de Cancerologia de Mexico	2011-12-31
NCT01535729	An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01535729	Completed	Hoffmann-La Roche	2014-06-30
NCT01525199	Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.	https://ClinicalTrials.gov/show/NCT01525199	Completed	AstraZeneca	2013-11-30
NCT01512420	An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)	https://ClinicalTrials.gov/show/NCT01512420	Completed	Hoffmann-La Roche	2015-02-28
NCT01510405	Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01510405	Active, not recruiting	Dartmouth-Hitchcock Medical Center	2020-12-31
NCT01488331	An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01488331	Completed	Hoffmann-La Roche	2013-11-30
NCT01482182	Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy	https://ClinicalTrials.gov/show/NCT01482182	Completed	Samsung Medical Center	2013-11-30
NCT01385722	Molecular Analysis of Thoracic Malignancies	https://ClinicalTrials.gov/show/NCT01385722	Enrolling by invitation	Stanford University	2031-06-30
NCT01358942	An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)	https://ClinicalTrials.gov/show/NCT01358942	Completed	Hoffmann-La Roche	2012-11-30
NCT01346280	Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs	https://ClinicalTrials.gov/show/NCT01346280	Completed	National Institutes of Health Clinical Center (CC)	NA
NCT01343914	An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy	https://ClinicalTrials.gov/show/NCT01343914	Completed	Hoffmann-La Roche	2011-12-31
NCT01333007	An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01333007	Completed	Hoffmann-La Roche	2013-05-31
NCT04430725	Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study	https://ClinicalTrials.gov/show/NCT04430725	Recruiting	M.D. Anderson Cancer Center	2023-01-01
NCT04430712	Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume	https://ClinicalTrials.gov/show/NCT04430712	Active, not recruiting	Massachusetts General Hospital	2021-03-31
NCT04405661	Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC	https://ClinicalTrials.gov/show/NCT04405661	Recruiting	Guangzhou Institute of Respiratory Disease	2021-05-31
NCT04324164	Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC	https://ClinicalTrials.gov/show/NCT04324164	Recruiting	Hunan Province Tumor Hospital	2021-03-24
NCT04324151	Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC	https://ClinicalTrials.gov/show/NCT04324151	Recruiting	Hunan Province Tumor Hospital	2021-03-24
NCT04324125	Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC	https://ClinicalTrials.gov/show/NCT04324125	Recruiting	Hunan Province Tumor Hospital	2021-03-24
NCT04322890	PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene Mutation Positive Advanced NSCLC	https://ClinicalTrials.gov/show/NCT04322890	Recruiting	Hunan Province Tumor Hospital	2021-03-24
NCT04322617	Anlotinib Plus PD-1 Antibody in Standard Chemotherapy Failure Advanced NSCLCï¼š the ATHENA Study	https://ClinicalTrials.gov/show/NCT04322617	Recruiting	Hunan Province Tumor Hospital	2021-03-24
NCT04322591	Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial	https://ClinicalTrials.gov/show/NCT04322591	Recruiting	Hunan Province Tumor Hospital	2021-03-24
NCT04322578	Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC	https://ClinicalTrials.gov/show/NCT04322578	Recruiting	Hunan Province Tumor Hospital	2021-03-24
NCT04317651	Crizotinib in ALK Rearranged Non-small-cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04317651	Recruiting	Fondazione Ricerca Traslazionale	2021-12-31
NCT04309422	Texture Features and PDL1 in CT-PET 18 FDG	https://ClinicalTrials.gov/show/NCT04309422	Completed	University Hospital, Montpellier	2018-10-01
NCT04291755	Development and Analysis of a Stool Bank for Cancer Patients	https://ClinicalTrials.gov/show/NCT04291755	Recruiting	Persephone Biosciences	2020-12-31
NCT04257864	Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04257864	Completed	Hellenic Cooperative Oncology Group	2010-05-31
NCT04238130	Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection	https://ClinicalTrials.gov/show/NCT04238130	Recruiting	Sun Yat-sen University	2022-12-18
NCT04207775	Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy	https://ClinicalTrials.gov/show/NCT04207775	Recruiting	AstraZeneca	2023-05-30
NCT04206787	The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04206787	Recruiting	Boehringer Ingelheim	2023-12-15
NCT04208854	Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT04208854	Recruiting	International Group of Endovascular Oncology	2020-04-18
NCT04197076	Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA	https://ClinicalTrials.gov/show/NCT04197076	Recruiting	Shanghai Chest Hospital	2021-05-01
NCT04189679	Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma	https://ClinicalTrials.gov/show/NCT04189679	Recruiting	University Hospital, Grenoble	2021-11-30
NCT04187768	Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04187768	Recruiting	Indiana University	2020-12-31
NCT04179890	The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib	https://ClinicalTrials.gov/show/NCT04179890	Active, not recruiting	Boehringer Ingelheim	2020-07-17
NCT04164186	Fully Automated Pipeline for the Detection and Segmentation of Non-Small Cell Lung Cancer (NSCLC) on CT Images	https://ClinicalTrials.gov/show/NCT04164186	Active, not recruiting	Maastricht University	2019-11-07
NCT04154163	Appropriate Dosing to Optimise Personalised Cancer Treatments	https://ClinicalTrials.gov/show/NCT04154163	Recruiting	University of Dundee	2020-07-30
NCT04151940	PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04151940	Recruiting	University of Washington	2021-06-01
NCT04145232	AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient’s Response to Immunotherapies.	https://ClinicalTrials.gov/show/NCT04145232	Recruiting	Ardigen	2020-06-30
NCT04136470	BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics	https://ClinicalTrials.gov/show/NCT04136470	Recruiting	Ardigen	2020-09-30
NCT04137718	Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation	https://ClinicalTrials.gov/show/NCT04137718	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	2022-10-20
NCT04116918	Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC	https://ClinicalTrials.gov/show/NCT04116918	Recruiting	Shanghai Changzheng Hospital	2021-09-30
NCT04087473	Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC	https://ClinicalTrials.gov/show/NCT04087473	Recruiting	National Cancer Centre, Singapore	2022-06-30
NCT04092465	Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)	https://ClinicalTrials.gov/show/NCT04092465	Completed	AHEPA University Hospital	2019-08-31
NCT04076228	Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients	https://ClinicalTrials.gov/show/NCT04076228	Recruiting	Kiang Wu Hospital	2020-01-01
NCT04069663	Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study	https://ClinicalTrials.gov/show/NCT04069663	Completed	University Hospital, Grenoble	2019-05-15
NCT04041297	Evaluation of NSCLC Patients’ Oxygen Uptake On-kinetics at Cycle-ergometer During Prehabilitation	https://ClinicalTrials.gov/show/NCT04041297	Recruiting	ADIR Association	2021-05-31
NCT04037150	Circulating DNA in Surgically Treated NSCLC	https://ClinicalTrials.gov/show/NCT04037150	Recruiting	Helsinki University Central Hospital	2020-12-31
NCT03989050	Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors	https://ClinicalTrials.gov/show/NCT03989050	Recruiting	University of Cologne	2020-08-31
NCT03987555	Paclitaxel Therapeutic Drug Monitoring in Cancer Patients	https://ClinicalTrials.gov/show/NCT03987555	Recruiting	Wake Forest University Health Sciences	2021-03-31
NCT03958565	Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.	https://ClinicalTrials.gov/show/NCT03958565	Recruiting	University of Colorado, Denver	2022-03-05
NCT03951233	K-RAS and EGFR in Lung Cancer	https://ClinicalTrials.gov/show/NCT03951233	Completed	Hellenic Cooperative Oncology Group	2012-12-31
NCT03951012	Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy	https://ClinicalTrials.gov/show/NCT03951012	Recruiting	University of Iowa	2021-04-30
NCT03940846	CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology	https://ClinicalTrials.gov/show/NCT03940846	Active, not recruiting	Maastricht University	2020-10-31
NCT03918304	Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS	https://ClinicalTrials.gov/show/NCT03918304	Recruiting	AstraZeneca	2024-06-30
NCT03911219	Study to Evaluate the Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) Under 1st-line Treatment With Atezolizumab and Platinum-based Chemotherapy	https://ClinicalTrials.gov/show/NCT03911219	Recruiting	iOMEDICO AG	2024-06-30
NCT03892096	Development and Validation of a qPCR Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer	https://ClinicalTrials.gov/show/NCT03892096	Active, not recruiting	Cadex Genomics	2020-11-01
NCT03877250	Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies	https://ClinicalTrials.gov/show/NCT03877250	Recruiting	Memorial Sloan Kettering Cancer Center	2021-03-31
NCT03844464	Safety and Efficacy of Lorbrena	https://ClinicalTrials.gov/show/NCT03844464	Recruiting	Pfizer	2023-08-11
NCT03836469	Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil	https://ClinicalTrials.gov/show/NCT03836469	Recruiting	Latin American Cooperative Oncology Group	2020-06-03
NCT03833934	Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance	https://ClinicalTrials.gov/show/NCT03833934	Recruiting	Addario Lung Cancer Medical Institute	2020-08-23
NCT03804554	A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab	https://ClinicalTrials.gov/show/NCT03804554	Active, not recruiting	Bristol-Myers Squibb	2019-06-30
NCT03791034	Cell Free DNA for the Diagnosis and Treatment in Early NSCLC	https://ClinicalTrials.gov/show/NCT03791034	Recruiting	Samsung Medical Center	2020-12-31
NCT03790397	Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive	https://ClinicalTrials.gov/show/NCT03790397	Completed	FundaciÃ³n GECP	2019-07-15
NCT03764917	NGS Combined With RNAseq on Tumor Immune Escape in NSCLC	https://ClinicalTrials.gov/show/NCT03764917	Active, not recruiting	Shanghai Pulmonary Hospital, Shanghai, China	2020-12-31
NCT03761901	Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium	https://ClinicalTrials.gov/show/NCT03761901	Completed	AstraZeneca	2019-06-19
NCT03746262	Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03746262	Completed	Wake Forest University Health Sciences	2018-08-10
NCT03740503	Genomic Investigation of Unusual Responders	https://ClinicalTrials.gov/show/NCT03740503	Active, not recruiting	University Health Network, Toronto	2020-11-30
NCT03741647	Sleep Apnea and Lung Cancer	https://ClinicalTrials.gov/show/NCT03741647	Active, not recruiting	Zagazig University	2020-11-30
NCT03721289	Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients	https://ClinicalTrials.gov/show/NCT03721289	Completed	AstraZeneca	2019-03-09
NCT03710629	A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes	https://ClinicalTrials.gov/show/NCT03710629	Recruiting	The First Affiliated Hospital of Guangzhou Medical University	2022-12-01
NCT03705806	Palliative Thoracic ImmunoRT	https://ClinicalTrials.gov/show/NCT03705806	Recruiting	University Health Network, Toronto	2020-09-15
NCT03692442	Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform	https://ClinicalTrials.gov/show/NCT03692442	Recruiting	Guangzhou Institute of Respiratory Disease	2019-01-31
NCT03679936	Diagnostic Significance of Single Center, Open and Prospective Evaluation of ^{18^{F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer}}	https://ClinicalTrials.gov/show/NCT03679936	Recruiting	Fifth Affiliated Hospital, Sun Yat-Sen University	2020-12-31
NCT03689439	Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer?	https://ClinicalTrials.gov/show/NCT03689439	Recruiting	Fudan University	2021-11-01
NCT03658460	Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers	https://ClinicalTrials.gov/show/NCT03658460	Recruiting	Aalborg University Hospital	2019-10-01
NCT03647592	Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03647592	Recruiting	Hunan Province Tumor Hospital	2021-08-31
NCT03647111	Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03647111	Recruiting	Hunan Province Tumor Hospital	2020-12-31
NCT03647098	Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03647098	Enrolling by invitation	Hunan Province Tumor Hospital	2020-12-31
NCT03645330	A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)	https://ClinicalTrials.gov/show/NCT03645330	Active, not recruiting	Chugai Pharmaceutical	2021-06-15
NCT03646994	Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03646994	Recruiting	Hunan Province Tumor Hospital	2020-12-31
NCT03616522	A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03616522	Completed	Abramson Cancer Center of the University of Pennsylvania	2019-02-18
NCT03609918	Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing	https://ClinicalTrials.gov/show/NCT03609918	Completed	Tianjin Medical University Cancer Institute and Hospital	2017-09-27
NCT03576937	Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study	https://ClinicalTrials.gov/show/NCT03576937	Recruiting	University Health Network, Toronto	2020-07-31
NCT03562819	Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).	https://ClinicalTrials.gov/show/NCT03562819	Completed	AstraZeneca	2019-06-07
NCT03512847	Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03512847	Recruiting	Zealand University Hospital	2021-01-31
NCT03504098	Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development of NSCLC Patients	https://ClinicalTrials.gov/show/NCT03504098	Recruiting	National Taiwan University Hospital	2020-07-31
NCT03499678	Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA	https://ClinicalTrials.gov/show/NCT03499678	Recruiting	HKGepitherapeutics	2020-12-01
NCT03492801	Collection of Blood Samples in Patients With Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03492801	Recruiting	University of Southern California	2020-12-11
NCT03485326	A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients	https://ClinicalTrials.gov/show/NCT03485326	Recruiting	AstraZeneca	2021-06-30
NCT03465241	ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS	https://ClinicalTrials.gov/show/NCT03465241	Recruiting	Sun Yat-sen University	2021-12-31
NCT03457220	An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03457220	Completed	AstraZeneca	2019-12-31
NCT03454685	The Role of Microbiota on the Development of Lung Cancer	https://ClinicalTrials.gov/show/NCT03454685	Recruiting	Wuhan Union Hospital, China	2020-01-30
NCT03451526	A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03451526	Completed	Tang-Du Hospital	2017-12-01
NCT03427567	A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03427567	Completed	Tongji Hospital	2017-12-01
NCT03429673	A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients	https://ClinicalTrials.gov/show/NCT03429673	Completed	China-Japan Friendship Hospital	2017-12-01
NCT03429192	A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03429192	Completed	Tianjin Chest Hospital	2018-03-30
NCT03413956	An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03413956	Completed	Jiangsu Cancer Institute & Hospital	2018-03-30
NCT01261585	Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT	https://ClinicalTrials.gov/show/NCT01261585	Completed	Centre Henri Becquerel	2009-11-30
NCT01260038	Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.	https://ClinicalTrials.gov/show/NCT01260038	Completed	University Hospital, Antwerp	2011-09-30
NCT01255150	Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01255150	Completed	National Institutes of Health Clinical Center (CC)	NA
NCT03872362	Radiomics Multifactorial Biomarker for Pulmonary Nodules	https://ClinicalTrials.gov/show/NCT03872362	Completed	Maastricht University	2019-01-11
NCT01194050	An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01194050	Completed	Hoffmann-La Roche	2013-07-31
NCT01167972	Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma	https://ClinicalTrials.gov/show/NCT01167972	Completed	AstraZeneca	2012-09-30
NCT01153399	A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).	https://ClinicalTrials.gov/show/NCT01153399	Completed	AstraZeneca	2014-12-31
NCT01146366	Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT01146366	Completed	Washington University School of Medicine	2014-10-31
NCT01139944	Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01139944	Completed	Alliance for Clinical Trials in Oncology	2014-01-31
NCT01139619	A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients	https://ClinicalTrials.gov/show/NCT01139619	Completed	AstraZeneca	2013-01-31
NCT01124669	Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate	https://ClinicalTrials.gov/show/NCT01124669	Completed	Eastern Cooperative Oncology Group	2010-07-13
NCT01112631	Prospective Study of Quality of Life in Non-small Cell Lung Cancer (NSCLC) Patients Treated With/Without Postoperative Radiotherapy	https://ClinicalTrials.gov/show/NCT01112631	Completed	Maria Sklodowska-Curie Institute - Oncology Center	2007-09-30
NCT01103089	Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)	https://ClinicalTrials.gov/show/NCT01103089	Completed	AstraZeneca	2010-12-31
NCT01081496	Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT01081496	Completed	AstraZeneca	2010-08-31
NCT01069835	Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN)	https://ClinicalTrials.gov/show/NCT01069835	Completed	AstraZeneca	2011-03-31
NCT01067794	Chemotherapy in Treating Patients With Lung Cancer	https://ClinicalTrials.gov/show/NCT01067794	Completed	Eli Lilly and Company	2012-07-31
NCT01065415	Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT01065415	Completed	Samsung Medical Center	NA
NCT01026467	Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT01026467	Completed	Wake Forest University Health Sciences	2014-05-31
NCT01023828	K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	https://ClinicalTrials.gov/show/NCT01023828	Completed	National Institute of CancerologÃa	2010-01-31
NCT00997230	Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m	https://ClinicalTrials.gov/show/NCT00997230	Completed	AstraZeneca	2012-10-31
NCT00973427	DNA Chip Based Prognosis of Lung Cancer	https://ClinicalTrials.gov/show/NCT00973427	Completed	Medical Prognosis Institute A/S	2014-09-30
NCT00960271	Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT00960271	Completed	University Hospital, Rouen	2010-12-31
NCT00956280	Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT00956280	Completed	AstraZeneca	2010-04-30
NCT00923884	Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer	https://ClinicalTrials.gov/show/NCT00923884	Completed	National Institutes of Health Clinical Center (CC)	NA
NCT00922025	Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients	https://ClinicalTrials.gov/show/NCT00922025	Completed	AstraZeneca	2010-12-31
NCT00897234	Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers	https://ClinicalTrials.gov/show/NCT00897234	Completed	University of Minnesota	2010-08-31
NCT00899756	Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT00899756	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2016-12-31
NCT00890903	Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)	https://ClinicalTrials.gov/show/NCT00890903	Completed	Pierre Fabre Pharma GmbH	2012-04-30
NCT00862030	CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT00862030	Completed	AHS Cancer Control Alberta	2011-01-31
NCT03798535	First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy	https://ClinicalTrials.gov/show/NCT03798535	Recruiting	AstraZeneca	2023-12-20
NCT03724604	NSE/Alb as a Prognostic Biomarker for Lung Cancer	https://ClinicalTrials.gov/show/NCT03724604	Recruiting	First Affiliated Hospital Xi’an Jiaotong University	2019-06-30
NCT03724500	Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03724500	Recruiting	Chang Gung Memorial Hospital	2020-12-31
NCT01106781	A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology	https://ClinicalTrials.gov/show/NCT01106781	Completed	AstraZeneca	2014-01-31
NCT00831909	Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN	https://ClinicalTrials.gov/show/NCT00831909	Completed	AstraZeneca	2010-07-31
NCT00831454	Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection	https://ClinicalTrials.gov/show/NCT00831454	Completed	Istituto Clinico Humanitas	2011-12-31
NCT04294108	Why in Hospital After VATS Lobectomy	https://ClinicalTrials.gov/show/NCT04294108	Recruiting	Rigshospitalet, Denmark	2020-09-16
NCT02751879	Real World Data on Gi(l)OtrifÂ® Dose Adjustment	https://ClinicalTrials.gov/show/NCT02751879	Completed	Boehringer Ingelheim	2017-09-30
NCT01522833	Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer	https://ClinicalTrials.gov/show/NCT01522833	Completed	SCRI Development Innovations, LLC	2015-02-28
NCT01505400	Integrated Molecular Profiling in Advanced Cancers Trial	https://ClinicalTrials.gov/show/NCT01505400	Active, not recruiting	University Health Network, Toronto	2021-01-31
NCT03916367	CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer	https://ClinicalTrials.gov/show/NCT03916367	Completed	Peking University Third Hospital	2018-12-15
NCT03870464	LIFE - Lung Cancer, Immunotherapy, Frailty, Effect	https://ClinicalTrials.gov/show/NCT03870464	Recruiting	University of Southern Denmark	2021-09-30
NCT03838588	The Tracking Molecular Evolution for NSCLC (T-MENC) Study	https://ClinicalTrials.gov/show/NCT03838588	Recruiting	Geneplus-Beijing Co. Ltd.	2021-12-31
NCT03727477	Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib	https://ClinicalTrials.gov/show/NCT03727477	Recruiting	Intergroupe Francophone de Cancerologie Thoracique	2020-06-30
NCT02689050	Optical Biopsy for Thoracic Lymph Nodes.	https://ClinicalTrials.gov/show/NCT02689050	Completed	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	2017-03-22
NCT02440854	Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings	https://ClinicalTrials.gov/show/NCT02440854	Active, not recruiting	Boehringer Ingelheim	2021-03-22
NCT04266691	Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04266691	Completed	Zhejiang Cancer Hospital	2015-12-31
NCT04023812	Stage III NSCLC RWE in Chinese Patients	https://ClinicalTrials.gov/show/NCT04023812	Recruiting	AstraZeneca	2022-05-30
NCT03939481	Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer	https://ClinicalTrials.gov/show/NCT03939481	Recruiting	Southwest Oncology Group	2025-02-28
NCT03725475	A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients	https://ClinicalTrials.gov/show/NCT03725475	Completed	AstraZeneca	2019-09-30
NCT03613467	Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients	https://ClinicalTrials.gov/show/NCT03613467	Completed	Tang-Du Hospital	2018-07-04
NCT03559647	The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy	https://ClinicalTrials.gov/show/NCT03559647	Active, not recruiting	Hoffmann-La Roche	2023-05-12
NCT00763607	Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT00763607	Completed	Istituto Clinico Humanitas	2008-02-29
NCT00759382	Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.	https://ClinicalTrials.gov/show/NCT00759382	Active, not recruiting	European Lung Cancer Working Party	2021-01-31
NCT00717847	A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib	https://ClinicalTrials.gov/show/NCT00717847	Completed	National University Hospital, Singapore	2013-04-30
NCT00717002	Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study	https://ClinicalTrials.gov/show/NCT00717002	Completed	National University Hospital, Singapore	2013-04-30
NCT00671242	Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake	https://ClinicalTrials.gov/show/NCT00671242	Completed	Gunma University	NA
NCT00641238	Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)	https://ClinicalTrials.gov/show/NCT00641238	Completed	State University of New York - Upstate Medical University	2011-02-28
NCT00602433	Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib	https://ClinicalTrials.gov/show/NCT00602433	Completed	Northwestern University	2009-08-31
NCT00603057	Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer	https://ClinicalTrials.gov/show/NCT00603057	Completed	University of Michigan Rogel Cancer Center	2013-09-30
NCT00579683	Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT00579683	Completed	Memorial Sloan Kettering Cancer Center	2016-02-29
NCT00572325	Concurrent Chemo-radiation Form NSCLC to a Individualized MLD	https://ClinicalTrials.gov/show/NCT00572325	Completed	Maastricht Radiation Oncology	NA
NCT00573040	Radiotherapy for NSCLC to a Individualized MLD	https://ClinicalTrials.gov/show/NCT00573040	Completed	Maastricht Radiation Oncology	NA
NCT00501319	Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery	https://ClinicalTrials.gov/show/NCT00501319	Completed	M.D. Anderson Cancer Center	2011-10-31
NCT00464282	Fluorine-18-Î±â€“Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer	https://ClinicalTrials.gov/show/NCT00464282	Completed	Gunma University	NA
NCT00450281	S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT00450281	Completed	Southwest Oncology Group	2012-07-31
NCT00419042	Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT00419042	Completed	Groupe Francais De Pneumo-Cancerologie	2006-09-30
NCT00418704	Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT00418704	Completed	Groupe Francais De Pneumo-Cancerologie	2006-06-30
NCT00409968	BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT00409968	Completed	M.D. Anderson Cancer Center	2019-10-31
NCT00388206	A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)	https://ClinicalTrials.gov/show/NCT00388206	Completed	Genentech, Inc.	2012-03-31
NCT00351598	Lung Tumour Volume Database	https://ClinicalTrials.gov/show/NCT00351598	Completed	Trans-Tasman Radiation Oncology Group (TROG)	2009-02-28
NCT00352391	Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients	https://ClinicalTrials.gov/show/NCT00352391	Completed	M.D. Anderson Cancer Center	2016-01-31
NCT00341380	Prevention of Tumor Spread Due to Lung Cancer Surgery	https://ClinicalTrials.gov/show/NCT00341380	Completed	National Institutes of Health Clinical Center (CC)	2007-04-13
NCT00280202	Detection of Genetic Markers of Lung Cancer	https://ClinicalTrials.gov/show/NCT00280202	Recruiting	University of Pittsburgh	2050-12-31
NCT00263731	Metabolomic Analysis of Lung Cancer	https://ClinicalTrials.gov/show/NCT00263731	Recruiting	University of Louisville	2025-12-31
NCT00252759	Iressa Case Control Study in Japan	https://ClinicalTrials.gov/show/NCT00252759	Completed	AstraZeneca	NA
NCT00222404	Pharmacogenomic Study Realized on “Non-small Cell Lung Carcinoma”	https://ClinicalTrials.gov/show/NCT00222404	Completed	University Hospital, Grenoble	NA
NCT00213733	Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT00213733	Completed	University Hospital, Strasbourg, France	NA
NCT00094822	Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT00094822	Completed	Amgen	2005-12-31
NCT00077324	Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions	https://ClinicalTrials.gov/show/NCT00077324	Completed	Alliance for Clinical Trials in Oncology	2011-11-30
NCT01936571	Usefulness of Blood Biomarkers for Overall Survival in NSCLC	https://ClinicalTrials.gov/show/NCT01936571	Completed	Maastricht Radiation Oncology	2014-02-28
NCT00071344	Analysis of Brain Metastasis in Patients With Lung Cancer	https://ClinicalTrials.gov/show/NCT00071344	Completed	National Institutes of Health Clinical Center (CC)	NA
NCT00818402	Non-small Cell Lung Cancer and Quality of Life	https://ClinicalTrials.gov/show/NCT00818402	Completed	University of Turku	2012-02-29

Registries

#If less then 500 registries

nct_id	brief_title	link	overall_status	source	primary_completion_date
NCT03824977	Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery	https://ClinicalTrials.gov/show/NCT03824977	Recruiting	University Hospital, Rouen	2018-11-21
NCT03334864	Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)	https://ClinicalTrials.gov/show/NCT03334864	Recruiting	Peking Union Medical College Hospital	2023-12-31
NCT03299478	Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03299478	Recruiting	University Hospital of North Norway	2024-11-30
NCT03235765	Cancer Panel From Blood of Lung Cancer Patients	https://ClinicalTrials.gov/show/NCT03235765	Active, not recruiting	Seoul National University Hospital	2019-03-10
NCT03125603	Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer	https://ClinicalTrials.gov/show/NCT03125603	Completed	Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain	2018-08-01
NCT03066297	Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03066297	Recruiting	Samsung Medical Center	2027-02-15
NCT02991924	Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer	https://ClinicalTrials.gov/show/NCT02991924	Active, not recruiting	National Cancer Center, Korea	2019-12-31
NCT02965391	Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients	https://ClinicalTrials.gov/show/NCT02965391	Completed	Peking University People’s Hospital	2017-09-30
NCT02778854	Liquid Biopsy for Detection of Driver Mutation in NSCLC	https://ClinicalTrials.gov/show/NCT02778854	Recruiting	Chinese PLA General Hospital	2018-12-31
NCT02777658	PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC	https://ClinicalTrials.gov/show/NCT02777658	Completed	AstraZeneca	2020-05-31
NCT02730897	Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLC	https://ClinicalTrials.gov/show/NCT02730897	Completed	University Hospital, Gasthuisberg	2016-10-31
NCT02622581	Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients	https://ClinicalTrials.gov/show/NCT02622581	Recruiting	AIO-Studien-gGmbH	2023-09-30
NCT02113852	Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients	https://ClinicalTrials.gov/show/NCT02113852	Completed	Guangdong Association of Clinical Trials	2016-05-31
NCT01963351	Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC	https://ClinicalTrials.gov/show/NCT01963351	Completed	University of Athens	2014-01-31
NCT01951755	Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC)	https://ClinicalTrials.gov/show/NCT01951755	Completed	University of Athens	2014-01-31
NCT01838577	Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study	https://ClinicalTrials.gov/show/NCT01838577	Active, not recruiting	European Organisation for Research and Treatment of Cancer - EORTC	2018-10-31
NCT01808677	Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy	https://ClinicalTrials.gov/show/NCT01808677	Completed	M.D. Anderson Cancer Center	2016-08-31
NCT04266483	Cancer Genome Atlas of China:Lung Cancer	https://ClinicalTrials.gov/show/NCT04266483	Recruiting	Xuanwu Hospital, Beijing	2022-11-08
NCT04216121	LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib	https://ClinicalTrials.gov/show/NCT04216121	Recruiting	Universitaire Ziekenhuizen Leuven	2023-02-28
NCT04153097	Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC	https://ClinicalTrials.gov/show/NCT04153097	Recruiting	First Affiliated Hospital of Zhejiang University	2020-11-30
NCT04137588	Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT04137588	Recruiting	Beijing Cancer Hospital	2022-03-01
NCT03995875	Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC	https://ClinicalTrials.gov/show/NCT03995875	Recruiting	AstraZeneca	2023-12-31
NCT03791151	Pharmacogenetics in Non Small Cell Lung Cancer	https://ClinicalTrials.gov/show/NCT03791151	Recruiting	Ain Shams University	2019-11-30
NCT03643484	IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy	https://ClinicalTrials.gov/show/NCT03643484	Active, not recruiting	AstraZeneca	2021-06-30
NCT03605602	A Real World Study Based on NGS (TRUMPRWS)	https://ClinicalTrials.gov/show/NCT03605602	Recruiting	Guangdong Association of Clinical Trials	2022-12-30
NCT03305380	Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth	https://ClinicalTrials.gov/show/NCT03305380	Recruiting	Maastricht Radiation Oncology	2020-12-01

intervention_type	Study_Count
Drug	1309
Drug\|placebo	143
Drug\|Radiation	121
Biological\|Drug	107
Biological	81
Radiation	76
Drug\|Other	59
Procedure	49
Drug\|Procedure	43
Other	35
Biological\|Drug\|Other	21
Drug\|Procedure\|Radiation	19
Device	18
Behavioral	13
Biological\|Drug\|placebo	13
Biological\|Drug\|Radiation	11
Biological\|Other	11
Diagnostic Test	9
Drug\|Other\|placebo	9
Drug\|Other\|Procedure	9
Drug\|placebo\|Radiation	8
Other\|Procedure	8
Procedure\|Radiation	8
Biological\|placebo	7
Device\|Drug	7
Drug\|Other\|Radiation	7
Biological\|Radiation	6
Other\|Radiation	6
Combination Product	5
Other\|Procedure\|Radiation	5
Dietary Supplement	4
Behavioral\|Other\|Procedure	3
Biological\|Other\|Radiation	3
Diagnostic Test\|Drug	3
Drug\|Genetic\|Other	3
Drug\|Other\|Procedure\|Radiation	3
Genetic	3
Behavioral\|Drug\|placebo	2
Biological\|Dietary Supplement\|Drug	2
Biological\|Drug\|Other\|placebo	2
Biological\|Drug\|Other\|Radiation	2
Biological\|Other\|Procedure\|Radiation	2
Combination Product\|Drug	2
Device\|Drug\|Radiation	2
Device\|Other	2
Dietary Supplement\|Drug	2
Drug\|Genetic\|Other\|Procedure	2
Behavioral\|Drug\|Other\|placebo	1
Behavioral\|Drug\|Other\|Procedure	1
Behavioral\|Radiation	1
Biological\|Combination Product\|Drug\|Other	1
Biological\|Device	1
Biological\|Device\|Drug\|Radiation	1
Biological\|Diagnostic Test	1
Biological\|Drug\|Genetic\|Other	1
Biological\|Drug\|Other\|Procedure	1
Biological\|Drug\|placebo\|Radiation	1
Biological\|Drug\|Procedure	1
Biological\|placebo\|Radiation	1
Biological\|Procedure	1
Combination Product\|Other	1
Device\|Drug\|Other	1
Device\|Drug\|Other\|Procedure	1
Device\|Drug\|Procedure\|Radiation	1
Device\|Other\|Radiation	1
Device\|Procedure	1
Device\|Radiation	1
Diagnostic Test\|Drug\|Other	1
Diagnostic Test\|Other\|Procedure	1
Dietary Supplement\|Drug\|Radiation	1
Dietary Supplement\|placebo	1
Drug\|Genetic	1
Drug\|Genetic\|Other\|placebo	1
Drug\|Genetic\|Other\|Procedure\|Radiation	1
Drug\|Genetic\|Procedure	1
Drug\|Other\|placebo\|Procedure	1

Number_of_Arms	Count_of_Studies
1	945
2	798
3	151
4	81
5	22
6	18
7	11
8	5
9	8
10	5
11	2
12	1
13	1
14	2
15	1
16	1
18	2
19	1
24	1
NA	238

Site_count	Study_Count
1	176
2	8
3	8
4	7
5	9
6	5
7	3
8	3
9	5
10	9
11	5
12	2
13	1
14	4
15	2
17	2
18	1
21	1
22	2
23	4
24	2
25	1
26	2
28	1
29	2
31	2
32	2
33	2
35	1
37	1
39	1
41	1
42	1
43	1
44	1
46	1
50	1
56	1
61	1
63	1
71	1
72	1
73	1
81	1
88	1
92	1
101	1
111	1
118	1
120	1
133	1
152	1
170	1
198	1
299	1
405	1
432	1

Number_of_Arms	Count_of_Studies
1	945
2	798
3	151
4	81
5	22
6	18
7	11
8	5
9	8
10	5
11	2
12	1
13	1
14	2
15	1
16	1
18	2
19	1
24	1
NA	238

Site_count	Study_Count
1	176
2	8
3	8
4	7
5	9
6	5
7	3
8	3
9	5
10	9
11	5
12	2
13	1
14	4
15	2
17	2
18	1
21	1
22	2
23	4
24	2
25	1
26	2
28	1
29	2
31	2
32	2
33	2
35	1
37	1
39	1
41	1
42	1
43	1
44	1
46	1
50	1
56	1
61	1
63	1
71	1
72	1
73	1
81	1
88	1
92	1
101	1
111	1
118	1
120	1
133	1
152	1
170	1
198	1
299	1
405	1
432	1

carcinoma, non-small-cell lung

Study Counts

Studies over Time by Start Date

Interventional Trials

Intervention Type

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Studies by Country

Sites per Study

Phase

Number of Arms

Enrollment Metrics by Phase

Trial Group Type

Intervention Model

Primary Purpose

Observational Studies

Studies by Country

Sites per Study

Enrollment Metrics

Observation Model

Time Perspective

Registries

Studies by Country

Sites per Study

Enrollment Metrics

Registry Model

Time Perspective

Follow-up

Overview of Studies

Interventional Trials

Observational Studiess

Registries

Number_of_Arms	Count_of_Studies
1	945
2	798
3	151
4	81
5	22
6	18
7	11
8	5
9	8
10	5
11	2
12	1
13	1
14	2
15	1
16	1
18	2
19	1
24	1
NA	238

Site_count	Study_Count
1	176
2	8
3	8
4	7
5	9
6	5
7	3
8	3
9	5
10	9
11	5
12	2
13	1
14	4
15	2
17	2
18	1
21	1
22	2
23	4
24	2
25	1
26	2
28	1
29	2
31	2
32	2
33	2
35	1
37	1
39	1
41	1
42	1
43	1
44	1
46	1
50	1
56	1
61	1
63	1
71	1
72	1
73	1
81	1
88	1
92	1
101	1
111	1
118	1
120	1
133	1
152	1
170	1
198	1
299	1
405	1
432	1